



## Natural killer cells in antitumour adoptive cell immunotherapy

Tamara J. Laskowski<sup>1</sup>, Alexander Biederstädt<sup>1,2</sup> and Katayoun Rezvani<sup>1</sup> ✉

**Abstract** | Natural killer (NK) cells comprise a unique population of innate lymphoid cells endowed with intrinsic abilities to identify and eliminate virally infected cells and tumour cells. Possessing multiple cytotoxicity mechanisms and the ability to modulate the immune response through cytokine production, NK cells play a pivotal role in anticancer immunity. This role was elucidated nearly two decades ago, when NK cells, used as immunotherapeutic agents, showed safety and efficacy in the treatment of patients with advanced-stage leukaemia. In recent years, following the paradigm-shifting successes of chimeric antigen receptor (CAR)-engineered adoptive T cell therapy and the advancement in technologies that can turn cells into powerful antitumour weapons, the interest in NK cells as a candidate for immunotherapy has grown exponentially. Strategies for the development of NK cell-based therapies focus on enhancing NK cell potency and persistence through co-stimulatory signalling, checkpoint inhibition and cytokine armouring, and aim to redirect NK cell specificity to the tumour through expression of CAR or the use of engager molecules. In the clinic, the first generation of NK cell therapies have delivered promising results, showing encouraging efficacy and remarkable safety, thus driving great enthusiasm for continued innovation. In this Review, we describe the various approaches to augment NK cell cytotoxicity and longevity, evaluate challenges and opportunities, and reflect on how lessons learned from the clinic will guide the design of next-generation NK cell products that will address the unique complexities of each cancer.

### Autologous chimeric antigen receptor (CAR) T cell therapy

A patient-specific cellular therapy in which the patient's own T cells are genetically modified to express a chimeric antigen receptor.

### Lymphopenic

A lower than normal number of lymphocytes in the blood.

<sup>1</sup>Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

<sup>2</sup>Department of Medicine III: Hematology and Oncology, School of Medicine, Technical University of Munich, Munich, Germany.

✉e-mail: [KRezvani@mdanderson.org](mailto:KRezvani@mdanderson.org)  
<https://doi.org/10.1038/s41568-022-00491-0>

Adoptive cell therapy using engineered immune effectors is a promising new approach to treat haematological and solid malignancies for which treatment options are limited<sup>1–9</sup>. Autologous chimeric antigen receptor (CAR) T cell therapy, the first to enter clinical translation and commercialization, has led to remarkable improvements in patients with aggressive B cell malignancies, producing long-term sustained remissions in many cases. However, despite these successes, challenges remain. The complex manufacturing process of CAR T cell therapy increases costs and lengthens the vein to vein time, thus representing an obstacle for patients who, owing to rapidly progressing disease, are in critical need of treatment. Furthermore, the requirement for the patient's own cells as the source material restricts eligibility, as many patients are often heavily pretreated and lymphopenic, and may not have sufficient cells to yield a viable product. In the clinic, CAR T cell-related cytokine-release syndrome (CRS) and neurotoxicities represent an additional concern, requiring inpatient monitoring. Given these limitations, there is growing interest in exploring cell sources that are off the shelf and could be applied universally. Because T cells recognize and mediate a response

against non-self via the T cell receptor (TCR), use of CAR T cells in the allogeneic setting requires additional genetic editing steps to remove the TCR to mitigate the risk of graft-versus-host disease (GvHD). Natural killer (NK) cells, on the other hand, recognize their targets in a human leukocyte antigen (HLA)-unrestricted manner and thus do not present these same risks, making them attractive candidates for universal cellular immunotherapy<sup>10</sup>. NK cell effector function is controlled by a complex array of activating and inhibitory receptors that can distinguish between healthy and 'stressed' cells<sup>11</sup>. The cumulative cues resulting from receptor–ligand engagements determine whether NK cells deliver a 'kill' or 'not kill' signal. Healthy cells are spared via recognition of self-major histocompatibility complex (MHC) class I molecules which bind inhibitory killer cell immunoglobulin-like receptors (KIRs) that signal to stop NK cell function. By contrast, through the mechanism of missing-self recognition, NK cells attack abnormal self-cells, such as tumour cells, which downregulate expression of MHC class I molecules in an attempt to evade T cell responses, and upregulate activating ligands that are induced by stress such as DNA damage or malignant transformation<sup>12–16</sup>.

These various attributes provide NK cells with unique advantages for allogeneic therapeutic applications. With the accelerated development of innovative strategies and the emergence of next-generation technologies that allow for deeper biological investigations, various NK cell products can be designed for cancer treatment. In this Review, we describe how these unique properties of NK cells are leveraged for adoptive NK cell immunotherapy, and provide an overview of the evolving engineering strategies to augment NK cell potency and persistence, as well as the efforts to redirect NK cell specificity to tumours through next-generation CAR molecules, engineered TCR and pre-complexing with cell engagers. Lastly, we conclude with a perspective on the challenges and opportunities ahead as we confront solid tumours and safeguard immune effector cells from the suppressive pressures within the tumour micro-environment, while also devising strategies to monitor and mitigate inadvertent safety concerns.

### Biological properties of NK cells

Despite the successes of engineered T cell immunotherapies<sup>1–8</sup>, the clinical benefit has been limited to a fraction of patients and a few indications, thus highlighting the need for new strategies. Leveraging innate immunity to broaden the scope of antitumour responses is an attractive option. Within the innate immune system, NK cells are specialized immune effector cells, and are suspected to have a role in tumour immunosurveillance<sup>10</sup>, as suggested by the correlation of low NK cell activity with increased cancer susceptibility and higher risk of metastasis observed in both preclinical and clinical studies<sup>17–19</sup>. NK cells develop from CD34<sup>+</sup> progenitor cells in the bone marrow, although it is as yet unclear whether they arise from a unique set of precursor cells or from multipotent progenitors that also give rise to T lymphocytes, B lymphocytes and myeloid cells<sup>20</sup>. Unlike T cells and NKT cells, NK cells lack expression of the clonotypic TCR and the associated CD3 complex responsible for signal transduction. NK cells are generally classified under a dichotomous distribution based on the relative expression of surface proteins CD56 and CD16: CD56<sup>bright</sup>CD16<sup>low/–</sup> (immunomodulatory, cytokine-producing) and CD56<sup>dim</sup>CD16<sup>+</sup> (cytotoxic)<sup>21</sup>. Recent advancements in high-parameter cytometry and single-cell proteo-genomics, however, have led to the understanding that NK cells may, in fact, exhibit greater phenotypic heterogeneity that extends beyond these two subsets, giving rise to diverse cell populations endowed with varying functional properties<sup>22</sup>.

NK cells possess strong cytotoxicity and, upon forming immunological synapses with targets, elicit a potent response through the release of cytolytic granules and cytotoxic cytokines<sup>23</sup>. Moreover, they can recognize antibody-coated cells through their FcγRIIIA (CD16) receptor and trigger antibody-dependent cellular cytotoxicity (ADCC) and cytokine production<sup>24</sup>. NK cells have also been described as ‘immune-regulatory’ because of their ability to produce an array of cytokines and chemokines, through which they help shape B cell and T cell responses, and impact the function of dendritic cells, macrophages and neutrophils<sup>11</sup>. This broad range

of attributes reveals the sophisticated network of biological mechanisms associated with NK cell function and supports the value of NK cells for immunotherapy.

**Memory-like function in NK cells.** Early studies reported memory-like responses by NK cells in mouse models of cytomegalovirus infection<sup>25,26</sup>, a behaviour not typically associated with innate immune cells. In these studies<sup>26,27</sup>, mouse NK cells, when stimulated with a combination of IL-12 and IL-18, acquired a functional phenotype characterized by increased production of IFNγ. Interestingly, after a resting phase, these cells were able to reactivate upon cytokine stimulation or engagement of activating receptors and exhibited an enhanced IFNγ response resembling the memory-like properties of adaptive immune cells. Later, Todd Fehniger’s group hypothesized that human NK cells should, likewise, be endowed with memory-like properties. Consistent with this hypothesis, their study demonstrated that human NK cells, preactivated with IL-12, IL-15 and IL-18, followed by 1–3 weeks rest, were able to generate a robust response driven by enhanced IFNγ production upon subsequent exposure to cytokines or to K562 leukaemia cells<sup>28</sup>. Since then, many more groups have described similar memory-like function in various immunological settings, including observations of such responses in humans<sup>29,30</sup>.

### NK cell source and donor selection

In patients with cancer, NK cells typically display a dysfunctional phenotype marked by altered gene expression profiles and reduced cytotoxic function<sup>31,32</sup>, thus diminishing the feasibility of autologous NK cell therapy applications. Moreover, autologous manufacturing platforms are cumbersome and may limit accessibility if patients are not able to provide sufficient cells to undergo downstream processing and engineering.

Because allogeneic NK cells do not cause GvHD, current NK cell therapy programmes rely largely on allogeneic sources to avoid the incumbrances associated with autologous approaches. There are various sources from which NK cells can be derived (FIG. 1), namely peripheral blood mononuclear cells<sup>28–30</sup>, cord blood<sup>28–30,33–37</sup>, immortalized cell lines<sup>38–40</sup>, haematopoietic stem and progenitor cells (HSPCs)<sup>33,34,41</sup> and induced pluripotent stem cells (iPSCs)<sup>42,43</sup>. All sources can provide clinically meaningful cell doses, are amenable to CAR receptor engineering and have transitioned into in-human studies. They, nevertheless, come with unique advantages and challenges, and may possess different underlying transcriptional, phenotypic and functional properties<sup>44</sup>.

NK-92, the first NK cell-based immunotherapy to receive Investigational New Drug approval by the US Food and Drug Administration (FDA) for clinical testing, is a homogeneous, immortalized NK lymphoma cell line that can be expanded ex vivo to achieve large cell numbers<sup>38</sup> (TABLE 1). NK-92 cells lack expression of most KIRs and are thus less likely to become inhibited, which makes them attractive for cell therapy use<sup>38</sup>. However, their cancerous origin raises safety concerns, and irradiation of NK-92-derived cell products prior to patient administration is required, which, in turn, can

#### Allogeneic setting

The therapy setting in which adoptive cell therapies are generated from material obtained from a different individual of the same species.

#### Graft-versus-host disease


(GvHD). A potentially fatal condition that results from the response of allogeneic T cells against the host tissues of recipients who are immunosuppressed, which can occur after adoptive cell therapy or allogeneic haematopoietic stem cell transplantation.

#### Killer cell immunoglobulin-like receptors

(KIRs). A family of polymorphic activating and inhibitory transmembrane proteins that regulate natural killer cell development and function through interactions with major histocompatibility complex class I molecules.

#### Induced pluripotent stem cells

(iPSCs). Cells that result from the reprogramming of adult somatic cells into an embryonic-like pluripotent stem cell state, capable of self-renewal and differentiation into tissues originated from the three germ layers (endoderm, mesoderm and ectoderm).



**Fig. 1 | Advantages and limitations arising from different sources of NK cells.** Natural killer (NK) cells can be derived from several different sources, each of which presents its own advantages and potential challenges. Chimeric antigen receptor (CAR) NK cells have successfully been engineered from different platforms including cord blood<sup>35,37</sup>, peripheral blood<sup>52,112,264</sup>, NK-92 cells<sup>39,265–274</sup> and induced pluripotent stem cell (iPSC)-derived NK cells<sup>43,48,49</sup>. ADCC, antibody-dependent cellular cytotoxicity; HSPC, haematopoietic stem and progenitor cells; MDACC, University of Texas MD Anderson Cancer Center.

negatively impact their long-term in vivo persistence and overall therapeutic potential<sup>37</sup>. Another disadvantage is that, owing to a lack of CD16 expression, NK-92 cells are devoid of the ability to mediate cell killing via ADCC.

NK cells can also be derived from CD34<sup>+</sup> progenitor cells upon in vitro differentiation<sup>33</sup>. In a first-in-human clinical trial, Dolstra et al. showed clinical efficacy in older patients with minimal residual disease-positive acute myeloid leukaemia (AML) who received adoptively transferred HSPC-NK cells<sup>34</sup>. Although preliminary results are encouraging, clinical studies exploring the safety and efficacy of HSPC-NK cells in larger patient populations and various indications will help determine the range of potential clinical applications for these cells. Future work will also need to address whether HSPC-NK cells can be effectively engineered to achieve enhanced tumour specificity.

iPSCs are an appealing source for NK cells given their clonal growth and high expansion capacity, as well as their ability to differentiate in vitro, allowing for the manufacturing of large numbers of homogeneous NK cell products. A potential disadvantage is that iPSC-derived NK cells often express low levels of endogenous CD16, although this can be mitigated through genetic engineering<sup>45</sup>. Another possible concern is that iPSCs may harbour DNA methylation signatures consistent with their somatic tissue of origin<sup>46</sup>. This ‘epigenetic memory’ could influence the development of specific cell lineages that differ from the donor cell, and should, therefore, be considered when employing iPSC platforms<sup>47</sup>. Nonetheless, a growing number of genetically engineered iPSC-NK cell candidates are emerging in preclinical studies, with a few that have transitioned into clinical trials<sup>48–51</sup>. In a phase I/II trial, iPSC-NK cells expressing CAR showed encouraging results in patients with relapsed or refractory (R/R)

Table 1 | Clinical studies investigating CAR-engineered NK cell therapy products

Molecular target	Disease	Construct	NK cell source	Clinical trial identifier and sponsor	First posted	Current status
CD7	CD7 <sup>+</sup> R/R leukaemia/lymphoma	CAR.7-CD28-4-1BB-CD3 $\zeta$	NK-92	NCT02742727 (REF. <sup>210</sup> ); PersonGen BioTherapeutics	2016	Unknown
CD19	R/R B-ALL	CAR.19-41BB-CD3 $\zeta$	Peripheral blood from haplo-identical donor	NCT00995137 (REF. <sup>211</sup> ); St Jude Children's Research Hospital, Memphis, TN	2009	Completed
CD19	R/R B-NHL	CAR.19-41BB-CD3 $\zeta$	Peripheral blood from haplo-identical donor	NCT01974479 (REF. <sup>212</sup> ); National University Health System	2013	Suspended for interim review
CD19	R/R CD19 <sup>+</sup> lymphoid malignancies	CAR.19-CD28-41BB-CD3 $\zeta$	NK-92	NCT02892695 (REF. <sup>213</sup> ); PersonGen BioTherapeutics	2016	Unknown
CD19	R/R ALL/CLL/B-NHL	CAR.CD19-CD28-CD3 $\zeta$ . iCasp9-IL15	Cord blood	NCT03056339 (REF. <sup>214</sup> ); MD Anderson Cancer Center	2017	Phase I portion completed; phase II recruiting Interim results reported 2020: ORR = 8/11 (73%) CR = 7/11 (64%) No CRS/ICANS/GvHD CAR NK cells in vivo persistence $\geq$ 1 year post infusion <sup>37</sup>
CD19	R/R B-NHL	Not disclosed	iPSC	NCT03824951 (REF. <sup>215</sup> ); Allife Medical Science and Technology	2019	Unknown
CD19	R/R B-NHL	Not disclosed	iPSC	NCT03690310 (REF. <sup>216</sup> ); Allife Medical Science and Technology	2018	Unknown
CD19	R/R B-NHL/B-ALL	CAR.19-OX40-CD3 $\zeta$ (NKX019)	Peripheral blood	NCT05020678 (REF. <sup>217</sup> ); Nkarta Therapeutics	2021	Recruiting
CD19	R/R B-NHL/CLL	CAR.19-NKG2D-2B4-CD3 $\zeta$ -IL15RF-hnCD16 (FT596 $\pm$ rituximab/obinutuzumab)	iPSC	NCT04245722 (REF. <sup>218</sup> ); Fate Therapeutics	2020	Recruiting Interim trial results 2021: $\geq 90 \times 10^6$ cells FT596 (n = 18) $\pm$ rituximab ORR = 13/18 (72%) CR = 8/18 (44%) including 3/5 (60%) in CAR T cell-naïve patients in the rituximab arm $\geq 90 \times 10^6$ cells FT596 monotherapy (n = 9) ORR = 7/9 (78%) CR = 3/9 (33%) No dose-limiting toxicities <sup>49</sup>
CD19	R/R B-NHL	Not disclosed	Not disclosed	NCT04639739 (REF. <sup>219</sup> ); Xinqiao Hospital of Chongqing	2020	Not yet recruiting
CD19	R/R B-NHL	Not disclosed	Peripheral blood from HLA-haplo-identical donor	NCT04887012 (REF. <sup>220</sup> ); Second Affiliated Hospital, School of Medicine, Zhejiang University	2021	Recruiting
CD19	R/R B-NHL	CAR.19.IL15 (full construct not disclosed)	Cord blood	NCT04796675 (REF. <sup>221</sup> ); Wuhan Union Hospital	2021	Recruiting
CD19	R/R B-NHL/ALL/CLL	Not disclosed	Not disclosed	NCT04796688 (REF. <sup>222</sup> ); Wuhan Union Hospital	2021	Recruiting
CD19	B-ALL	Not disclosed (QN-019a $\pm$ rituximab)	Not disclosed	NCT05379647 (REF. <sup>223</sup> ); Zhejiang University	2022	Recruiting

Table 1 (cont.) | Clinical studies investigating CAR-engineered NK cell therapy products

Molecular target	Disease	Construct	NK cell source	Clinical trial identifier and sponsor	First posted	Current status
CD19	R/R B-NHL	CAR.19 HLA-I KO/HLA-E knock-in HLA-II KO/EGFR safety switch knock-in Soluble IL-15 knock-in (full construct not disclosed)	iPSC	NCT05336409 (REF. <sup>224</sup> ); Century Therapeutics	2022	Not yet recruiting
CD20	R/R B-NHL	hnCD16 (full construct not disclosed) (FT516 + rituximab)	iPSC	NCT04023071 (REF. <sup>225</sup> ); Fate Therapeutics	2019	Recruiting Interim results 2021: ≥90 × 10 <sup>6</sup> cells FT516 + rituximab CAR T cell naive patients (n = 10) ORR = 8/10 (80%) CR = 5/10 (50%) Prior CAR T cells (n = 8) ORR = 3/8 (38%) CR = 3/8 (38%) <sup>51</sup>
CD22	R/R B-NHL	Not disclosed	iPSC	NCT03692767 (REF. <sup>226</sup> ); Allife Medical Science and Technology	2018	Unknown
CD19/CD22	R/R B-NHL	Not disclosed	iPSC	NCT03824964 (REF. <sup>227</sup> ); Allife Medical Science and Technology	2019	Unknown
CD33	R/R AML	CAR.33-CD28-4-1BB-CD3ζ	NK-92	NCT02944162 (REF. <sup>228</sup> ); PersonGen BioTherapeutics	2016	Unknown Interim results 2018: No durable responses in 3 patients with R/R AML No significant adverse events <sup>49</sup>
CD33	R/R AML	Not disclosed	Not disclosed	NCT05008575 (REF. <sup>229</sup> ); Xinqiao Hospital of Chongqing	2021	Recruiting
CD33/CLL1	R/R AML	Not disclosed	Not disclosed	NCT05215015 (REF. <sup>230</sup> ); Wuxi People's Hospital	2022	Recruiting
CD70	R/R AML/MDS/B-NHL	CAR.CD70-IL15 (full construct not disclosed)	Cord blood	NCT05092451 (REF. <sup>231</sup> ); MD Anderson Cancer Center	2021	Not yet recruiting
BCMA	R/R B-NHL	Not disclosed	iPSC	NCT03559764 (REF. <sup>232</sup> ); Allife Medical Science and Technology	2018	Unknown
BCMA	R/R multiple myeloma	CD8-41BB-CD3ζ	NK-92	NCT03940833 (REF. <sup>233</sup> ); Asclepius Technology Company Group	2019	Recruiting
BCMA	R/R multiple myeloma	Not disclosed	Not disclosed	NCT05008536 (REF. <sup>234</sup> ); Xinqiao Hospital of Chongqing	2021	Recruiting
BCMA	R/R multiple myeloma	Undisclosed (FT576 ± daratumumab)	iPSC	NCT05182073 (REF. <sup>235</sup> ); Fate Therapeutics	2022	Recruiting
CD38/SLAMF7	R/R multiple myeloma R/R AML	hnCD16A-IL-15RF-CD38 <sup>-/-</sup> ; full construct not disclosed (FT538 ± daratumumab/ elotuzumab)	iPSC	NCT04614636 (REF. <sup>236</sup> ); Fate Therapeutics	2020	Recruiting
NKG2D ligands	R/R AML/MDS	CAR.NKG2D-OX40-CD3ζ (NKX101)	Peripheral blood	NCT04623944 (REF. <sup>237</sup> ); Nkarta Therapeutics	2020	Recruiting

Table 1 (cont.) | Clinical studies investigating CAR-engineered NK cell therapy products

Molecular target	Disease	Construct	NK cell source	Clinical trial identifier and sponsor	First posted	Current status
NKG2D ligands	Advanced solid tumours	NKG2D.CD8.DAP12	Peripheral blood (autologous and allogeneic)	NCT03415100 (REF. <sup>238</sup> ); The Third Affiliated Hospital of Guangzhou Medical University	2018	Interim results reported 2019: Reduction of ascites generation/decrease in ascites tumour cell counts in 2 patients with colorectal cancer (RECIST: SD); complete metabolic response (PET/CT) of liver lesion in 1 patient with metastatic colorectal cancer (RECIST: SD) <sup>239</sup>
NKG2D ligands	Refractory metastatic colorectal cancer	Not disclosed	Not disclosed	NCT05213195 (REF. <sup>240</sup> ); Zhejiang University	2022	Recruiting
NKG2D ligands	R/R AML	Not disclosed	Cord blood	NCT05247957 (REF. <sup>241</sup> )	2022	Recruiting
Muc1	Advanced solid tumours	Not disclosed	Not disclosed	NCT02839954 (REF. <sup>242</sup> ); PersonGen BioTherapeutics	2016	Unknown
HER2	Recurrent HER2 <sup>+</sup> glioblastoma	CAR.HER2.CD28.CD3ζ	NK-92	NCT03383978 (REF. <sup>243</sup> ) (CAR2BRAIN); Johann Wolfgang Goethe University Hospital	2017	Recruiting
PSMA	Castration-resistant prostate cancer	Not disclosed	iPSC	NCT03692663 (REF. <sup>244</sup> ); Allife Medical Science and Technology	2018	Not yet recruiting
Mesothelin	Ovarian cancer	Not disclosed	iPSC	NCT03692637 (REF. <sup>245</sup> ); Allife Medical Science and Technology	2018	Not yet recruiting
CD276	Ovarian cancer	hnCD16; full construct not disclosed (FT516 + enoblituzumab)	iPSC	NCT04630769 (REF. <sup>246</sup> ); Fate Therapeutics	2020	Recruiting
ROBO1	Advanced solid tumours; pancreatic cancer	Not disclosed	Not disclosed	NCT03940820 (REF. <sup>247</sup> ); NCT03931720 (REF. <sup>248</sup> ); NCT03941457 (REF. <sup>249</sup> ); Asclepius Technology Company Group	2019	Recruiting
PDL1	Advanced solid tumours	hnCD16; full construct not disclosed (FT516 + avelumab)	iPSC	NCT04551885 (REF. <sup>250</sup> ); Fate Therapeutics	2020	Active
PDL1/PD1	Gastro-oesophageal junction cancer; advanced HNSCC	CAR.PDL1-FcεR1y (full construct not disclosed) + pembrolizumab	Modified NK-92	NCT04847466 (REF. <sup>251</sup> ); National Cancer Institute	2021	Recruiting
Oncofetal trophoblast glycoprotein (5T4)	Advanced solid tumours	Not disclosed	Not disclosed	NCT05194709 (REF. <sup>252</sup> ); Wuxi People's Hospital	2022	Recruiting
SARS-CoV-2 S protein; NKG2D ligands	COVID-19	CAR.NKG2D-ACE2-GM-CSF.IL15 (full construct not disclosed)	Cord blood	NCT04324996 <sup>253</sup> ); Chongqing Public Health Medical Center	2020	Recruiting

ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; BCMA, B cell maturation antigen; CAR, chimeric antigen receptor; CD38<sup>-/-</sup>, CD38 knockout; CLL, chronic lymphocytic leukaemia; CR, complete remission; CRS, cytokine-release syndrome; DAP12, DNAX-activation protein 12; GvHD, graft-versus-host disease; HLA, human leukocyte antigen; hnCD16, high-affinity, non-cleavable CD16; HNSCC, head and neck squamous cell carcinoma; ICANS, immune effector cell-associated neurotoxicity syndrome; IL15RF, IL15 receptor fusion; iPSC, induced pluripotent stem cell; KO, knockout; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; NK, natural killer; ORR, objective response rate; PSMA, prostate specific membrane antigen; R/R, relapsed or refractory; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

diffuse large B cell lymphoma, both as monotherapy and in combination with CD20-targeting agents<sup>13,49</sup>.

Primary NK cells can be harvested from peripheral blood (PB-NK cells)<sup>28–30,36</sup> or from umbilical cord blood

(CB-NK cells)<sup>33–35,37</sup>. CB-NK cells are available frozen off the shelf through blood banks, whereas PB-NK cells require apheresis of healthy donors and donor-specific collection. PB-NK cells served as the platform for

**Apheresis**

The process that allows for collection of specific components from blood, such as white blood cells, by separating the cellular and soluble fractions, retaining what is of interest and returning the remainder to circulation.

**Chimeric antigen receptors (CARs).**

Genetically engineered cell surface receptors designed to recognize specific proteins on tumour cells.

the very first successful delivery of a CAR construct into NK cells in work led by Dario Campana in 2005 (REF.<sup>52</sup>) and, today, PB-NK cells provide the basis for various products currently in clinical testing (TABLE 1). Cord blood NK cells have a proven track record for CAR-redirected antitumour cytotoxicity and clinical activity, as pioneered by our group<sup>35,37</sup>. In our study, we demonstrated potent clinical efficacy of genetically engineered cord blood-derived CD19-CAR NK cells against R/R CD19<sup>+</sup> lymphoid malignancies in an ongoing phase I/II clinical trial<sup>37</sup>.

NK cells derived from all of these sources have been shown to have advantages and disadvantages for adoptive cell therapy applications. Having various options for source material confers a degree of versatility to the design of therapeutic strategies, allowing platforms to be specifically tailored to address the needs of each patient population and disease indication.

It is important to note that inter-donor variability may influence NK cell profiles and, thus, impact clinical outcomes. Therefore, a thorough understanding of product characteristics is critical to define biomarkers indicative of greater potency and persistence. From an immunological perspective, donor-derived NK cells might prove advantageous when administered across HLA-KIR genotypic boundaries as HLA-KIR ligand disparity might help overcome tumour immune evasion. Early into the journey of NK cell-based immunotherapy, the field recognized a dramatically reduced probability of post-transplant AML relapse in

recipients of HLA haplotype-mismatched grafts with KIR ligand incompatibility<sup>53</sup>. Although KIR-HLA genotype-informed donor selection remains an area of active investigation<sup>54-57</sup>, evidence suggests a potential benefit of this approach in the setting of T cell-depleted allogeneic haematopoietic stem cell transplantation (alloHSCT)<sup>58-66</sup>. Further work is needed to determine whether this strategy can be successfully adopted into NK cell therapy pipelines.

**Enhancing NK cell fitness and antitumour function**

**Chimeric antigen receptors.** Chimeric antigen receptors (CARs) are synthetic fusion proteins comprising an extracellular antigen-recognition domain and intracellular signalling moieties that trigger cell activation. Most commonly, the single-chain variable fragment (scFv) from a desired antibody is used for the antigen-binding domain, although many CAR modalities comprising the extracellular portion of native cellular receptors have also been constructed, leveraging the natural specificity of receptor-ligand interactions<sup>67-69</sup>. CARs can be expressed on immune effector cells for the purpose of reprogramming their specificity to a particular target (FIG. 2a). CAR-engineered T cell therapeutics were the first to emerge, with various products developed for immuno-oncology applications<sup>1-8</sup>. The field has since expanded, and NK cells have also been integrated into gene engineering pipelines<sup>70,71</sup>. CARs conventionally designed for T cells (comprising CD3 $\zeta$  and T cell





Fig. 2 | **Strategies to redirect NK cell specificity.** Natural killer (NK) cell specificity towards tumour cells can be redirected using different strategies. **a,b** | Chimeric antigen receptor (CAR) NK cell<sup>35,37,43,112,264</sup> (panel **a**) and T cell receptor (TCR) NK cell<sup>94</sup> (panel **b**) approaches both build upon stable genetic engineering to endow NK cells with synthetic receptors that recognize extracellular and intracellular tumour antigens, respectively. **c** | Bi-specific and tri-specific engagers<sup>96,98-100,102,103,105,106,275</sup> deploy two-directional or three-directional antibodies which crosslink NK cells with their respective tumour cell targets and circumvent the need for complex genetic editing. HLA, human leukocyte antigen; MHC, major histocompatibility complex; scFV, single-chain variable fragment.



**Fig. 3 | Principles and strategies for CAR design.** **a, b** | Chimeric antigen receptor (CAR) molecules have evolved dramatically over the past two decades, from simple first-generation designs<sup>276</sup> (panel **a**), to second-generation<sup>52,277,278</sup> and third-generation<sup>39,279</sup> CARs with added co-stimulatory molecules (panel **b**) and, finally, to current-generation CAR designs resembling a modular system that encompasses optimized extracellular domains for target recognition, intracellular co-stimulatory molecules for effective natural killer (NK) cell activation and added payloads which can enhance NK cell functionality. **c–e** | Current strategies leverage the core principles of CAR signalling and functionality, and provide

innovative methods to improve tumour recognition and enhance cell activation, using sophisticated construct designs to allow targeting of multiple tumour antigens<sup>69,280</sup> (panel **c**), provide cytokine support<sup>35,37</sup> (panel **e**) and activate auxiliary cytotoxicity pathways. Integration of logic-gated circuits to guide selective killing of targeted malignant cells while sparing healthy tissues may lead to improved safety profiles<sup>90,92,93</sup> (panel **d**). aCAR, activating chimeric antigen receptor; AML, acute myeloid leukaemia; DAP12, DNAX-activation protein 12; EMCN, Endomucin; HLA, human leukocyte antigen; HSC, haematopoietic stem cell; iCAR, inhibitory chimeric antigen receptor; scFV, single-chain variable fragment.

co-stimulatory molecules) have been used for generation of CAR NK cells, and studies have demonstrated that these cells can target tumours with efficacy and specificity, while maintaining a desirable safety profile<sup>37</sup> (FIG. 3a).

Motivated by these encouraging results, there is growing interest in designing CARs based on activating signals associated with NK cell biology (FIG. 3b). Examples of such an approach include DNAX-activation protein 12 (DAP12) and DAP10, which have been used in place of CD3 $\zeta$  in some studies<sup>72–76</sup>. These adapter proteins are intracellular signalling domains that function via recruitment of PI3K and are associated with activating molecules such as Nkp44, activating KIRs (KIR2DS and KIR3DS) and NKG2C (REFS.<sup>72,76</sup>). Similar to CD3 $\zeta$ , DAP12 also contains immuno-tyrosine activation motifs (ITAMs) that, once phosphorylated, initiate a cascade of signals that culminate in the release

of cytotoxic granules and pro-inflammatory cytokines such as TNF $\alpha$  and IFN $\gamma$ <sup>72</sup>. DAP10, although not possessing an ITAM domain, has been shown to induce potent killing activity in NK cells via signalling through the NKG2D–DAP10 axis<sup>76</sup>.

In the past few years, the behaviour of CARs, once anchored on the cell surface, has garnered considerable interest, especially following observations that, in some cases, CAR T cells demonstrated an elevated basal level of activation independent of antigen engagement, referred to as tonic signalling<sup>77–81</sup>. Although studies continue to explore potential causes of this phenomenon, it has been reported that CARs may incorporate into the TCR–CD3 complex via the CD3 $\zeta$  domain and may augment T cell activation<sup>82,83</sup>. More recently, studies have shown that the CD28 transmembrane domain, present in some CAR frameworks, mediates CAR heterodimerization

**Tonic signalling**  
The constitutive signalling mediated by a chimeric antigen receptor in a ligand-independent manner.



with endogenous CD28 and, thereby, triggers T cell activation<sup>84,85</sup>. These observations suggest that CARs are not static on the cell membrane but, rather, are prone to interacting with endogenous receptors. Although not much is yet known regarding these types of receptor associations in NK cells, it is conceivable that CARs may form synergistic partnerships with any of the many activating receptors on the membrane of NK cells, resulting in cooperative activation.

Efforts have also focused on refining CAR-based strategies, motivated by learnings from clinical translation of this therapy, which have prompted investigations into approaches to overcome the challenges experienced in the patient. One critical obstacle to CAR-based cell therapy is antigen escape, a process through which tumours, via antigen loss or downregulation, evade the immune response. Various strategies have been employed to address this issue. Targeting multiple antigens is a viable approach to both increase the stringency of tumour detection and extend therapeutic benefit (FIG. 3c). This is often accomplished either by expressing a bi-cistronic construct that encodes for two separate CARs (each specific for a different antigen on the tumour and linked to two separate signalling endodomains) or by expressing a single CAR containing bi-specific recognition domains, each targeting a different antigen in tandem and linked to a single signalling endodomain<sup>86</sup>. Dual-CAR approaches afford greater design flexibility, accommodating combinations of signalling domains and receptor formats. Each CAR may be formatted to provide both activating and co-stimulatory signals upon target engagement. Alternatively, *trans*-signalling formats separate these two signals and require engagement to both antigens for full activation. With bi-specific CARs, the antigen-binding moieties are linked to a single receptor, often a second or third-generation CAR<sup>87,88</sup>. In either approach, considerations regarding antigen density, membrane localization and protein structure are important to ensure both CARs bind their targets efficiently at the immune synapse. Although most of these innovative CAR-based approaches have focused on T cells, it is plausible to anticipate that these systems can also be applied to NK cells.

Strategies for improving the control of CAR-mediated activation have also been explored, especially with a focus on minimizing toxicities resulting from on-target, off-tumour effects. Promoting selective targeting, via the use of logic-gated CARs, has been shown to mitigate some of these problems in the context of CAR T cells<sup>89–93</sup> (FIG. 3d). A recent study presented preliminary findings showing the feasibility of controlling CAR NK activity when applying an 'OR' and 'NOT' logic gated CAR gene circuit approach<sup>92,93</sup>. In this work, the team targeted FLT3 and/or CD33 on AML blasts via bivalent CARs and employed an inhibitory CAR to bind an antigen on healthy haematopoietic stem cells (HSCs) and elicit a 'NOT signal' to prevent cell killing<sup>92,93</sup>.

One key limitation of CAR-based approaches is that, for the most part, detection capability is limited to surface proteins. Intracellular antigens, which are presented in the form of peptide–HLA complexes, are naturally detected via the TCR. Engineering NK cells

to express a TCR could allow detection of such peptides (FIG. 2b). TCR-guided NK-92 cells have recently been shown to mediate successful antitumour responses<sup>94</sup>. Although additional studies are warranted to validate the clinical applicability of this approach, one potential advantage is that, because NK cells do not possess endogenous TCR, mispairing issues that have been reported in TCR-engineered T cells<sup>95</sup> will likely not be a concern. A downside, however, is that NK cells are not equipped with the full signalling machinery found in T cells, thereby potentially compromising the ability to be potently activated via a synthetic TCR.

**NK cell engagers.** NK cells can also be directed to tumour sites via engagers that elicit a strong NK cell-mediated antitumour response by triggering an activating receptor on the NK cell, while simultaneously binding a target antigen on the tumour cell<sup>96–100</sup> (FIG. 2c). Additional NK engager strategies include tri-specific and tetra-specific designs that aim to strengthen the antitumour effect by targeting multiple antigens on the tumour or by cross-linking cytokine moieties to support NK expansion and survival<sup>101–105</sup>. The use of cell engagers bypasses the need for engineering and does not require vector-mediated gene transfer, therefore representing a simpler and less costly manufacturing process that can deliver a product capable of inducing CAR-like activity.

Various preclinical studies have shown promising results when employing NK cell engagers to target haematological and solid malignancies<sup>96–106</sup>. Recent work demonstrated a robust NK cell-mediated response against primary patient-derived AML blasts by employing a tri-specific molecule targeting CLEC12A on AML cells and activating NK cells through a humanized anti-CD16 single-domain antibody and IL-15 (REF.<sup>105</sup>). Moreover, a trifunctional engager targeting two NK activating receptors, CD16 and Nkp46, was shown to drive potent antitumour response, culminating in efficient control of tumour growth in vivo in the setting of solid and metastatic malignancies in preclinical models<sup>106</sup>.

Recently, our group demonstrated that CB-NK cells, when complexed with AFM13 — a bi-specific engager binding CD16 on NK cells and CD30 on leukaemia or lymphoma targets — exhibited enhanced killing of CD30<sup>+</sup> tumour cells, leading to CAR-like responses<sup>100</sup>. We have since translated this approach to the clinic for treatment of R/R CD30<sup>+</sup> Hodgkin lymphoma and non-Hodgkin lymphoma (NHL) (NCT04074746 (REF.<sup>107</sup>)). As more strategies transition into clinical trials, it will be important to also evaluate the durability of the antitumour effect of engager-loaded NK cells and determine whether multiple treatments are required for sustained therapeutic benefit.

**Cytokine armouring.** Whereas CAR and TCR engineering technologies seek to enhance NK cell function by genetically redirecting their specificity, there are also initiatives that aim to effectively prime NK cells *ex vivo* and/or *in vivo* to sustain optimal antitumour function and persistence. It is well described that freshly isolated NK cells have lower cytolytic capacity compared with NK cells that have been primed<sup>108</sup>. One approach to address

#### Logic gated

A term derived from electronics that refers to implementation of a Boolean strategy to execute a logical function on one or more input signals to generate a single output signal.

this limitation is cytokine-mediated activation, and various methods are currently under investigation<sup>29,100,109–114</sup>. Ex vivo expansion of NK cells with combinations of IL-2, IL-15 and IL-21 supplementation shows that these cytokines enhance cytotoxic function and support high proliferation rates while maintaining cells in a healthy, non-exhausted state<sup>115</sup>.

It has now become clear that, when cultured in the presence of IL-12/15/18, PB-NK cells shift to a phenotype referred to as cytokine-induced memory-like NK cells<sup>29</sup>. Cytokine-induced memory-like NK cells have shown clinical efficacy in patients with R/R relapsed myeloid neoplasias both in the pre-transplant and post-transplant setting<sup>29,30</sup>. Engineering memory-like NK cells to express CAR augments antitumour responses leading to increased potency against NK-resistant malignancies<sup>111,112</sup>. Furthermore, in our own clinical trial employing the NK cell engager AFM13, preactivation of NK cells with IL-12/15/18 to induce memory programmes led to enhanced responses against CD30<sup>+</sup> lymphomas<sup>100</sup> (FIG. 2c) (NCT04074746 (REF.<sup>107</sup>)).

Although these data strongly point to the advantage of cytokine priming, continuous ex vivo stimulation renders NK cells ‘cytokine-addicted’ and leads to decreased persistence when these cells are infused in the absence of in vivo cytokine support<sup>115</sup>. To avoid this problem and still leverage the benefits of cytokine activation, the field has turned to genetic engineering, through which NK cells are modified to produce cytokines that will support cell potency, proliferation and persistence (FIG. 3e). This autocrine support has garnered notable interest, and CAR-engineered NK cells are emerging armed with supplemental cytokine signalling<sup>35,37,48,49</sup>. Cytokine armouring can be programmed such that soluble cytokines are released into the environment or are engineered in membrane-bound form to induce response upon cell to cell interaction<sup>116</sup>. In soluble form, cytokines that are produced by engineered NK cells can mediate a bystander effect and, thereby, activate other immune effector cells — such as T cells or myeloid cells — that are present in the tumour microenvironment (TME), thus potentially further augmenting the antitumour response<sup>117</sup>. Our group, as well as others, has demonstrated that IL-15-armoured CAR NK cells exhibit superior persistence in vivo in preclinical models when compared with CAR alone<sup>35,48,49</sup>. These findings were confirmed in a clinical study of patients with CD19<sup>+</sup> lymphoid malignancies, in many of whom we detected CAR NK cells in circulation a year after treatment<sup>37</sup>. With each cytokine armouring approach, it is important to determine optimal cytokine-dosing strategies that will support increased function and persistence, but will not compromise NK cell functionality by inducing metabolic exhaustion, as has been previously reported<sup>118</sup>.


**Overcoming immunosuppression.** The TME consists of a harsh metabolic landscape characterized by a heterogeneous mix of immunosuppressive metabolites, glucose and amino acid deprivation, hypoxia and acidity, which, in concert, prevent effective antitumour immunity. In solid tumours specifically, hypoxia is a common driver of immune cell dysfunction. It has been shown

that NK cell function is impaired in the hypoxic TME, in part due to the increased influx of suppressor cells such as myeloid-derived suppressor cells (MDSCs), regulatory T cells (T<sub>reg</sub> cells) and M2 macrophages in the TME as well as a direct impact of hypoxia on NK cell function<sup>119–122</sup>. Inhibition of hypoxia-responsive HIF1 $\alpha$  signalling in NK cells has been reported to enhance NK cell potency and unleash NK cell-mediated antitumour function<sup>123</sup>.

Tumours often display an aberrant metabolic behaviour that results in high levels of lactic acid, depletion of vital nutrients and an increase in concentrations of toxic catabolites, adenosine and reactive oxygen species<sup>109</sup>. In addition, the uncontrolled proliferation, dysfunctional vasculature and presence of immunosuppressive cell subsets contribute to the dismal fate of immune effector cells that venture into the TME. To overcome the detrimental effects of metabolic immunosuppression, current strategies focus primarily on two areas: altering the metabolic constitution of the tumour or modifying gene expression programmes in immune cells to shield them from the suppressive metabolites in the TME (FIG. 4a). Studies have shown that high levels of lactate dehydrogenase (LDH) in the blood and the TME correlate with poor outcomes for patients with melanoma and low response to checkpoint therapy<sup>124</sup>. Although still in the preclinical phase, glycolytic inhibitors and LDH blockers may provide an opportunity to favourably modulate the TME. A recent study showed that treatment of patient-derived melanoma cells with a lactate dehydrogenase A (LDHA) inhibitor, GSK2837808A, led to improved T cell antitumour cytotoxicity both in vitro and in vivo<sup>125</sup>. Lactate levels in the TME can also be decreased by targeting its transporters, MCT1 and MCT4, as has been shown for AstraZeneca’s AZD3965 compound, currently under investigation in the clinic (NCT01791595 (REF.<sup>126</sup>)).

Adenosine, a by-product of ATP metabolism, is generated via the activity of ectonucleotidases CD39 and CD73. Under the hypoxic conditions of the TME, expression of these enzymes is upregulated as part of the hypoxia-driven purinergic signalling pathway, resulting in the accumulation of extracellular adenosine, which in turn acts as a negative regulator of T cell and NK cell function in the TME, suppressing their metabolism and effector function<sup>127–130</sup>. Interestingly, adenosine contributes to activation of suppressor cells such as T<sub>reg</sub> cells, M2 macrophages and MDSCs, all resident populations within the TME. Therapeutic strategies for overcoming adenosine-mediated immunosuppression include blocking CD73 on tumour cells via small-molecule inhibitors or with antagonistic antibodies, both of which are currently under clinical investigation (NCT04148937 (REF.<sup>131</sup>), NCT03454451 (REF.<sup>132</sup>) and NCT03616886 (REF.<sup>133</sup>)). Furthermore, in preclinical studies, genetic editing to delete the adenosine A2A receptor in both CAR T cells and CAR NK cells has shown promise for improving the potency and antitumour efficacy of these cells<sup>134–137</sup> (FIG. 4a).

TGF $\beta$  signalling is another mechanism of immunosuppression within the TME that has a deleterious effect on NK cell function. Knockdown of the TGF $\beta$ -induced



**Fig. 4 | Genetic engineering strategies to overcome suppressors of NK cell function. a–f** Immune cell function is severely compromised by the hostile tumour microenvironment (TME)<sup>134</sup>. Current strategies leverage engineering tools to disrupt suppressive signals in the TME (panel **a**) and improve immune cell homing into tumour beds by ectopic expression of chemokine receptors (panel **d**). A selection of natural killer (NK) cell-relevant pathways that have been targeted through genetic engineering is shown. Genetic engineering strategies that include targeted ablation of inhibitory checkpoints<sup>156,164,167,168</sup> (panels **b,c**) as well as disruption of extracellular receptors which sense inhibitory stimuli including TGFβ<sup>140,141</sup> and adenosine<sup>135</sup> (panel **a**) have been shown preclinically to effectively target pathways to enhance metabolic fitness and persistence of NK cells, and

efforts are ongoing to advance these findings into the clinic. Ablation of endogenous receptors allows for combinatorial therapeutic approaches, such as by rendering immune cells resistant to corticosteroid-induced immunosuppression (panel **e**), a principle previously established in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-directed cytotoxic T lymphocytes (CTLs)<sup>281</sup>. Knockout of CD38 (panel **f**) renders NK cells resistant to CD38-mediated fratricide, which enables combination strategies of NK cells and anti-CD38-targeting monoclonal antibodies in the context of treating multiple myeloma<sup>50</sup>. B<sub>reg</sub> cell, regulatory B cell; MDSC, myeloid-derived suppressor cell; NKG2A, CD94/NK group 2 member A receptor; TIGIT, T cell immunoreceptor with immunoglobulin and ITIM domains; T<sub>reg</sub> cell, regulatory T cell.

miR-27a-5p led to improved NK cytotoxicity in vitro and in vivo<sup>138</sup>. Additionally, NK cells equipped with a high-affinity dominant-negative TGFβ receptor can resist the effects of TGFβ and retain their potency<sup>139</sup>. Similarly, our group successfully rendered CB-NK cells immune to TGFβ signalling by targeted deletion of the TGFβ receptor (*TGFBR2*)<sup>140</sup>. We subsequently provided in vivo evidence that disruption of TGFβ signalling safeguards NK cell cytotoxicity in a mouse model of glioblastoma<sup>141</sup>.

As we seek to modulate immunometabolism in the TME, it is important to achieve a physiologic balance, as some metabolites are an essential component of normal metabolism. Although many strategies are still under development, it is plausible that a combined approach involving TME modulation and NK cell engineering will lead to reduced immunosuppression and will support robust immune cell activity.

**Checkpoint disruption.** Tumours have evolved sophisticated mechanisms to evade immune surveillance, including the engagement of immune checkpoints, which may restrain NK cells in a similar manner as has been described for T cells. Striving to translate the clinical successes seen with the blockade of T cell-associated immune checkpoints PD1 and CTLA4, several groups have explored the potential of modulating these regulatory circuits in the context of NK cells<sup>142–149</sup> (FIG. 4b). Although some studies point to their role as functional suppressors, their overall relevance in NK cell biology is still under debate<sup>146,150</sup>. With some likelihood, the signalling networks that underpin NK cell activation constitute a more nuanced picture in which these predominantly T cell markers act in concert with various other NK cell regulators<sup>151</sup>. Other regulators which have been investigated include TIM3 (REFS.<sup>152,153</sup>), T cell immunoreceptor with immunoglobulin and ITIM domains

## Licensing

A process of education in maturing natural killer (NK) cells that is driven by the interaction of inhibitory receptors and self-major histocompatibility complex class I molecules, which potentiates NK cell responses to activating signals.

(TIGIT)<sup>136,153–156</sup> and LAG3 (REF.<sup>157</sup>), and their targeting using monoclonal antibodies has been shown to reverse tumour-induced NK dysfunction *in vitro*.

Inhibitory KIRs are potent negative regulators of NK cell function and can override any concomitant activating signal when engaged with HLA class I ligands. Given their prominent role in suppressing NK cell function, inhibitory KIRs have attracted considerable interest. Lirilumab, an anti-panKIR2D antibody, functions to skew the diverse and often opposing signalling cues perceived by NK cells towards net activation by blocking these inhibitory KIRs<sup>158</sup>. In two early-phase clinical trials, however, Lirilumab failed to elicit clinically meaningful responses<sup>159,160</sup>. One potential reason for these results might stem from the important role of inhibitory KIRs in NK cell education and licensing. Under this assumption, prolonged KIR inhibition due to continuous KIR blockade by Lirilumab might negatively affect NK cell function<sup>161,162</sup>.

Similar to KIR molecules, CD94/NK group 2 member A receptor (NKG2A) is another prominent negative NK cell regulator, which, when bound to its cognate ligand HLA-E, restrains NK cell cytotoxicity. Monalizumab specifically disrupts this interaction and led to a promising 31% objective response rate in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck when administered in combination with cetuximab<sup>163</sup>. Monalizumab is currently being tested against other solid tumours including colorectal cancer and non-small-cell lung cancer as well as post alloHSCT.

Common to these approaches is the reliance on monoclonal antibodies to modulate the patients' immune cells, a strategy that requires multiple infusions owing to their limited *in vivo* half-life. With advances in genetic editing capabilities, NK cells can be stably modified to regulate biological mechanisms that augment NK cell effector function. One example is the genetic disruption of the inhibitory receptor NKG2A, which led to superior tumour control in xenograft mouse models inoculated with HLA-E<sup>+</sup> tumours<sup>164</sup> (FIG. 4b). Moreover, building on seminal work that established CIS (cytokine-inducible SH2-containing protein) as a critical negative regulator of NK cell function<sup>165,166</sup>, we and others successfully engineered NK cells<sup>167,168</sup> lacking this intracellular cytokine checkpoint. The resulting CAR NK cells exhibited enhanced metabolic fitness and increased antitumour activity (FIG. 4c).

These studies foreshadow the potential of targeted genetic perturbations to modulate NK cell biology. Going forward, we anticipate that unbiased high-throughput discovery approaches will elucidate the functional consequences of specific genetic interventions in a more systematic manner to, ultimately, inform the design of the next generation of NK cell immunotherapies.

**Enhancing NK cell trafficking to tumours.** The ability of NK cells to traffic to and penetrate tumour beds is a critical prerequisite for effective antitumour immunity and has been linked to improved clinical outcomes<sup>169–173</sup>. NK cells, similar to other immune cells, are guided towards tumour sites by the dynamic

interplay of chemokine receptors and their cognate ligands secreted in the TME<sup>174–177</sup>. A growing body of work has, in recent years, investigated how modulation of these interactions may be harnessed to augment effective homing to the tumour. Whereas earlier studies focused on the expansion-induced upregulation of chemokine receptors<sup>178,179</sup> as well as transient transfection methods<sup>180,181</sup>, the swift loss of chemokine expression owing to internalization and degradation<sup>182</sup> has led to the increasing adoption of genetic engineering strategies to stably equip NK cells with ectopic chemokine receptors<sup>182,183</sup> (FIG. 4d). Today, the available studies provide encouraging preclinical evidence to support chemokine receptor modulation to enhance NK cell trafficking into tumour beds across a broad range of hard to treat tumours including multiple myeloma<sup>184,185</sup>, glioblastoma<sup>182</sup>, renal cell carcinoma<sup>183</sup>, pancreatic ductal adenocarcinoma<sup>186</sup> and ovarian cancer<sup>187</sup>.

Despite these advances, three important obstacles remain. First, chemotactic gradients rely on adequate tumour perfusion, and microthrombi-induced circulation deficits may require strategies to increase tumour micro-perfusion<sup>182</sup>. Second, the release of chemokines from the TME follows distinct tumour-specific kinetics, and intratumoural chemokine levels may need to be artificially boosted to robustly attract engineered NK cells<sup>179</sup>. Recent work has addressed this concern by locally augmenting chemokine concentrations using a mesothelin-targeting antibody fusion protein loaded with CXCL16, which is cleaved in the TME upon tumour cell engagement<sup>186</sup>. Furthermore, recent work has highlighted the application of radiation-induced CXCL8 to enhance NK cell migration to the tumour<sup>188</sup>. Last, chemokine–receptor interactions may be context-specific, either promoting or abrogating NK cell homing depending on the specific tumour type in question, as has been previously observed<sup>184,185</sup>. Future research will need to address these important questions and, ultimately, validate whether the overall promising findings can prevail in the context of the complex and dynamic interplay of chemokines within the human body.

### Clinical lessons learned

CAR T cell therapy has led to remarkable clinical outcomes, with some patients achieving decade-long remissions in the presence of sustained CAR T cell persistence<sup>1–9</sup>. This new form of cellular immunotherapy has also shown potential for treatment of various cancers, driving the development of an ever-expanding number of new strategies to build on these successes<sup>189–191</sup>. The CAR T cell experience has elucidated many requirements for successful development of safe and efficacious cell therapies and has also revealed critical challenges related to mechanisms of resistance and barriers to immune effector cell persistence<sup>192,193</sup>. Knowledge gained from the clinical journey with CAR T cells has contributed to the emergence of novel cell therapy modalities. Over the past decade, the field has seen NK cells emerge as a strong new therapeutic candidate, possessing biological properties that may help overcome some of the limitations seen with T cell-based

approaches. One noteworthy finding is that early clinical data suggest that NK cells are well suited for use in the allogeneic therapy setting as no major adverse events have been reported thus far in ongoing clinical studies<sup>194</sup>. Although safety results are encouraging, further investigations are required to elucidate whether allogeneic NK cells are capable of evading recipient T cell rejection for long-term persistence. A growing number of clinical studies have shown safety and efficacy of NK cells derived from peripheral blood mononuclear cells, cord blood, iPSCs, HSPCs and cell lines in the treatment of haematological malignancies<sup>28–30,33,34,37,39,48,49</sup>. Moreover, we have learned that, similar to their T cell counterparts, NK cells are quite amenable to genetic modification and numerous clinical candidates have been engineered to target the tumour with greater precision (by expressing CAR) and to increase persistence (through cytokine armouring). In addition, continuous efforts to enhance trafficking to tumour sites (through chemokine receptor editing) (FIG. 4d) and to shield against suppressive factors in the TME (through checkpoint inhibition, metabolic reprogramming (FIG. 4a) and hypoxia tolerance) may lead to enhanced benefits in the clinic. NK cells may also differentiate to a memory-like phenotype that naturally extends the persistence of NK cell function and confers the ability to recall an antitumour response upon antigen re-encounter. Memory NK cells are currently under clinical evaluation in the treatment of leukaemia. Moreover, memory-like NK cells pre-complexed with engager molecules provide an alternative to achieving CAR-like specificity without the need for lengthy manufacture<sup>100</sup>, and

in the clinic, this strategy is driving responses comparable with those seen for CAR T cells and CAR NK cells. Importantly, irrespective of the approach, NK cell therapies have consistently demonstrated a favourable safety profile, and, to date, with no observed CRS or GvHD.

Although tremendous progress has been made, and in a short time NK cells have become an important tool for immuno-oncology, most of the successes reported are limited to haematological malignancies, much like the initial function of CAR T cells. However, there have been challenges. Not all patients respond to NK cell therapy, and some who do, eventually relapse. What are the mechanisms underlying tumour resistance and relapse? Are tumour cells, and, likewise, therapeutic NK cells, evolving in the course of their interactions? Understanding the biological underpinnings that influence patient response is critical to answering these questions. In the current era of single-cell multi-omic capabilities, we are poised to see these challenges as, in fact, opportunities (BOX 1). Interrogating therapy evolution through a combination of genomic, proteomic and epigenomic profiling might offer valuable insights into changes that permanently ‘scar’ NK cells into a state of exhaustion and hypo-responsiveness to the tumour, as previously observed in T cells<sup>195,196</sup>. Indeed, we might also identify epigenetic roots to metabolic reprogramming that results in low bioenergetic reserves and decreased persistence. Once these mechanisms are elucidated, strategizing ways to reverse their effects and rescue cell function, or identifying favourable gene edits that intercept harmful interactions, will play a pivotal role in maximizing the benefit of cellular immunotherapies. Furthermore, implementing combination therapy approaches may provide a strategy for achieving a synergistic effect and increasing the efficacy of engineered adoptive NK cell therapies (TABLE 2). Integration of antibodies or small-molecule inhibitors to prevent metabolite-driven immunosuppression, or blockade of checkpoint and immunosuppressive mechanisms (FIG. 4b,e), for instance, might lead to a multifaceted outcome: boosting CAR NK cell function, hindering signals from suppressive cells in the TME and supporting the function of other immune effector cells<sup>197–199</sup>. Lastly, engineering NK cells to become resistant to CD38-mediated fratricide will enable NK cell-based treatment approaches to be combined with anti-CD38 monoclonal antibodies and allow NK cell immunotherapy to move into earlier lines of treatment in the setting of multiple myeloma<sup>50</sup> (FIG. 4f).

Although many clinical trials are still in the early stages, through an iterative process we will be able to learn directly from patients what the barriers posed by each cancer are and take this information back to the laboratory where therapies can be further refined into applicable solutions to real-life challenges. Knowledge gained from these investigations will serve as the foundation upon which future clinical studies are built and will be critical to achieving success as we move forward and take aim at solid tumours. Through cellular engineering strategies and combination therapy approaches, NK cell adoptive therapies for solid tumours will also need to address and overcome challenges related to poor

#### Box 1 | Forward genetic screens to inform the design of next-generation NK cell therapies

CRISPR-enabled functional genetic screens allow the systematic interrogation of cancer-intrinsic vulnerabilities towards anti-neoplastic treatments in an unbiased large-scale manner, thereby extending the scope of traditional hypothesis-driven strategies. Over the past decade, many groups have applied these tools to better understand the molecular mechanisms of therapeutic resistance including against T cell immunotherapy<sup>282–289</sup>. Recently, this approach has been adapted to decipher cancer-specific vulnerabilities towards natural killer (NK) cell immunotherapy leveraging an orthogonal multiplexed approach, in which a diverse pool of DNA-barcoded cancer cell lines (PRISM) was examined simultaneously to identify shared transcriptional programmes that correlate with response. These studies hold an intriguing implication as they lay the groundwork for future biomarker-guided approaches to help identify and stratify patients whose tumours might be particularly susceptible to NK cell immunotherapy<sup>290</sup>.

Translating CRISPR screening to primary immune cells, however, has proved much more challenging. First, primary immune cells are inherently more resistant to stable genetic editing, a prerequisite to reliably uncover genotype–phenotype relationships. Furthermore, limited ex vivo culture time periods prohibit long-term assays to achieve the necessary phenotypic resolution. In 2018, the work of two groups overcame this long-standing limitation. Guide Swap technology, which delivers Cas9 ribonucleoproteins pre-complexed to non-targeting single guide RNA, was successfully used to screen human primary CD4<sup>+</sup> T cells<sup>291</sup>. Another group applied a hybrid approach to screen primary human T cells by combining lentiviral library delivery with Cas9 electroporation<sup>292</sup>. Recently, this approach was translated to chimeric antigen receptor (CAR)-engineered T cells to investigate drivers of functional exhaustion in a reciprocal glioblastoma stem cell screen<sup>293</sup>. In its latest iteration, pooled knock-in screens now allow the concurrent assessment of functional consequences of integrating a multitude of transgenes<sup>294,295</sup>. Going forward, these tools will serve as invaluable platforms to decipher fundamental immune cell biology and, in turn, can inform the design of next-generation cellular therapies.

Table 2 | Combinatorial strategies to enhance CAR NK cell therapeutic potency

Type	Combinatorial agents	Molecular rationale	Refs.
IMiDs	Lenalidomide	Enhance ADCC	254,255
Epigenetic modulators	Azacytidine	Upregulate tumour-associated antigens	256,257
	Decitabine	Restore and enhance tumour immunogenicity	
	Vorinostat (HDACi)		
Oncolytic viruses	Oncolytic adenovirus	Augment tumour immunogenicity and enhance recruitment into tumour beds by promoting inflammation in the TME	258,259
		Dendritic cell-mediated NK cell activation/reversal of NK cell anergy	
Small-molecule inhibitors	GSK3i	Upregulate CD57, drive NK cell maturation Enhance ADCC	260,261
Immune checkpoint inhibitors	PDL1 antibody	Direct pro-cytotoxic effect on NK cells	149
	PD1/PDL1 blockade	Unleash NK cell antitumour immunity	148
	Anti-NKG2A antibody		262
	Monalizumab	159,160,263	
	Anti-KiR antibody		
	Lirilumab		
	TIGIT	154	

An overview of different combinatorial agents that might be used to further enhance CAR NK cell immunotherapy. Although no concrete dosing schedules have yet been established clinically, combination of one or multiple of these agents with CAR NK cell infusions is conceivable to augment NK cell cytotoxicity and increase tumour immunogenicity via pro-inflammatory mechanisms to, ultimately, improve antitumour potency. ADCC, antibody-dependent cellular cytotoxicity; CAR, chimeric antigen receptor; GSK3i, glycogen synthase kinase-3 inhibitor; HDACi, histone deacetylase inhibitor; IMiD, immunomodulatory drug; KiR, killer cell immunoglobulin-like receptor; NK, natural killer; NKG2A, CD94/NK group 2 member A receptor; TIGIT, T cell immunoreceptor with immunoglobulin and ITIM domains; TME, tumour microenvironment.

tumour trafficking and limited persistence and effector function in the immunosuppressive TME.

**Ensuring genomic fidelity in NK cell therapies**

Given the vast scope and the accelerated pace at which novel insights into fundamental NK cell immunobiology are generated, we anticipate an increase in novel engineered cell products. It is therefore increasingly important to establish platforms for screening and characterization of products to identify unintended genetic alterations resulting from off-target nuclease activity. Concerns that some genomic changes may inadvertently lead to oncogenic mutations continue to reverberate in the background as the field advances. To address this need, the US National Institutes of Health (NIH) have launched the Somatic Cell Genome Engineering (SCGE) programme with two main missions: first to provide financial aid to researchers to facilitate the transfer of genome editing technologies to the clinic, and second, to support the development of more comprehensive assays to investigate potential adverse biological effects that could result from the use of these tools<sup>200</sup>. In addition, various platforms to investigate genome editing fidelity have been developed, such as GUIDE-Seq<sup>201</sup>, CIRCLE-Seq<sup>202</sup> and rhampSeq<sup>203</sup> that

rely on sequencing technologies to unbiasedly identify sites in the genome where double-stranded breaks may have occurred. Moreover, unintended genetic rearrangements may be elucidated by assays such as linear amplification-mediated high-throughput genome-wide translocation sequencing (LAM-HTGTS)<sup>204</sup>. As these tools continue to evolve and newer ones are developed, the implementation of such assays in cell therapy development will be of paramount importance to ensure greater understanding of safety and efficacy of cellular products such as engineered NK cell therapies.

**Concluding remarks**

Engineered cellular immunotherapies continue to experience tremendous growth, with diverse modalities quickly advancing from preclinical studies into clinical testing. The recent report of in vivo editing of hepatocytes in patients with transthyretin amyloidosis epitomizes the latest frontier in the cell and gene therapy space<sup>205</sup>. In a related effort, an approach to enable T cell-targeted in vivo CAR transfection using lipid nanoparticles has been developed for the generation of fibroblast activating protein (FAP)-redirected CAR T cells to target cardiac remodelling in the context of myocardial injury<sup>206,207</sup>. Moreover, recent work has demonstrated that Nipah lentivirus vectors redirected to CD3, CD8 and CD4 could specifically deliver therapeutic genes (such as CAR and TCR) to T cell populations in vivo<sup>208</sup>. These technical innovations provide a new approach to off-the-shelf personalized therapies, in which targeted viral vectors are readily available to be administered to patients upon need, thereby bypassing the requirement for extensive ex vivo manufacturing, reducing costs and expediting therapy delivery. It is conceivable that targeted in vivo editing may also be applied to tumour cells, driving modifications that will restore their sensitivity to anti-neoplastic agents or eliminate resistance mechanisms. Although current initiatives have mostly focused on CAR T cell therapy, in vivo engineering might also be applicable to NK cell-based therapies, such as to boost endogenous NK cell function and persistence, or to increase tumour sensitivity to NK cell-mediated cytotoxicity.

As the field continues to innovate at a rapid rate, it is important to keep abreast of potential safety risks associated with these various gene editing strategies, as concerns associated with possible off-target effects are very relevant. The recent halt of multiple ongoing cell therapy trials owing to cases of chromosomal abnormalities, treatment-associated AML/myelodysplastic syndrome (MDS) or malignant transformation of the infused CAR T cell product<sup>209</sup> justify these concerns and serve as reminders of the importance of closely studying the safety of engineered products. Moreover, it is critical that cell therapy programmes implement pipelines for systematic screening of products to assess potential unwanted genetic modifications that may result in deleterious effects. Leveraging resources such as the NIH's SCGE programme may provide the initial support needed to launch these initiatives.

Although NK cell-based immunotherapy is well positioned as a safe off-the-shelf antitumour therapy,

important questions remain open. Elucidating the key parameters that determine NK cell potency and persistence will be important as the field progresses into developing approaches to address challenges specific to each disease indication. Moreover, decisions related to use of co-stimulatory signal, cytokine armoring and combination with other therapeutic modalities will play a role in maximizing the longevity and benefit of adoptively transferred NK cells. Finally, it will be critical to develop

and implement optimal methods for expansion and cryopreservation of NK cells to ensure that high product quality is sustained. Logistically, for emerging NK cell therapy programmes to succeed, it will be essential to establish multidisciplinary team structures comprising researchers, clinicians and regulatory officials to jointly sketch a wholistic path to clinical translation.

Published online 25 July 2022

- Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N. Engl. J. Med.* **378**, 439–448 (2018).
- Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. *N. Engl. J. Med.* **380**, 45–56 (2019).
- Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *N. Engl. J. Med.* **377**, 2531–2544 (2017).
- Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. *N. Engl. J. Med.* **378**, 449–459 (2018).
- June, C. H., O'Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. *Science* **359**, 1361–1365 (2018).
- Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory multiple myeloma. *N. Engl. J. Med.* **382**, 1331–1342 (2020).
- Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. *N. Engl. J. Med.* **384**, 705–716 (2021).
- Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. *N. Engl. J. Med.* **380**, 1726–1737 (2019).
- Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4<sup>+</sup> CAR T cells. *Nature* **602**, 503–509 (2022). **This landmark article reports the sustained remissions and in vivo persistence of CD19-CAR T cells for more than 10 years after infusion, and hence highlights the long-term durability of clinical responses achieved using genetically engineered T cells.**
- Malmberg, K.-J. et al. Natural killer cell-mediated immunosurveillance of human cancer. *Semin. Immunol.* **31**, 20–29 (2017).
- Lanier, L. L. Up on the tightrope: natural killer cell activation and inhibition. *Nat. Immunol.* **9**, 495–502 (2008).
- Joncker, N. T., Fernandez, N. C., Treiner, E., Vivier, E. & Raulet, D. H. NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. *J. Immunol.* **182**, 4572–4580 (2009). **This study elucidates the nature of NK cell responsiveness, which relies on the integration of both inhibitory and activating signalling cues to ensure self-tolerance and immunosurveillance over abnormal cells.**
- Joncker, N. T., Shifrin, N., Delebecque, F. & Raulet, D. H. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. *J. Exp. Med.* **207**, 2065–2072 (2010).
- Burshtyn, D. N. et al. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. *Immunity* **4**, 77–85 (1996).
- Yokoyama, W. M. & Kim, S. How do natural killer cells find self to achieve tolerance? *Immunity* **24**, 249–257 (2006).
- Brodin, P., Lakshmikanth, T., Johansson, S., Kärre, K. & Höglund, P. The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. *Blood* **113**, 2434–2441 (2009).
- Imai, K., Matsuyama, S., Miyake, S., Suga, K. & Nakachi, K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. *Lancet* **356**, 1795–1799 (2000).
- Guerra, N. et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. *Immunity* **28**, 571–580 (2008).
- López-Soto, A., Gonzalez, S., Smyth, M. J. & Galluzzi, L. Control of metastasis by NK cells. *Cancer Cell* **32**, 135–154 (2017).
- Abel, A. M., Yang, C., Thakar, M. S. & Malarkannan, S. Natural killer cells: development, maturation, and clinical utilization. *Front. Immunol.* **9**, 1869 (2018).
- Dalle, J.-H. et al. Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. *Pediatr. Res.* **57**, 649–655 (2005).
- Strauss-Albee, D. M. et al. Human NK cell repertoire diversity reflects immune experience and correlates with viral susceptibility. *Sci. Transl. Med.* **7**, 297ra115–297ra115 (2015).
- Prager, I. & Watzl, C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. *J. Leukoc. Biol.* **105**, 1319–1329 (2019).
- Wang, W., Erbe, A. K., Hank, J. A., Morris, Z. S. & Sondel, P. M. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. *Front. Immunol.* **6**, 368 (2015).
- O'Leary, J. G., Goodarzi, M., Drayton, D. L. & von Andrian, U. H. T cell- and B cell-independent adaptive immunity mediated by natural killer cells. *Nat. Immunol.* **7**, 507–516 (2006). **This seminal study demonstrates that NK cells can mediate durable recall responses upon antigen re-exposure, establishing the concept of NK cell adaptive memory.**
- Sun, J. C., Beilke, J. N. & Lanier, L. L. Adaptive immune features of natural killer cells. *Nature* **457**, 557–561 (2009). **This important article reveals self-renewing 'memory' NK cell subsets that can undergo secondary expansion and elicit strong adaptive immune responses upon viral challenge when transferred to naive animals.**
- Cooper, M. A. et al. Cytokine-induced memory-like natural killer cells. *Proc. Natl Acad. Sci. USA* **106**, 1915–1919 (2009). **This work pioneers the concept of cytokine-induced memory-like NK cells which elicit robust recall responses when transferred to naive hosts.**
- Romee, R. et al. Cytokine activation induces human memory-like NK cells. *Blood* **120**, 4751–4760 (2012).
- Romee, R. et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. *Sci. Transl. Med.* **8**, 357ra123 (2016).
- Shapiro, R. M. et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for post-transplant relapse. *J. Clin. Invest.* <https://doi.org/10.1172/JCI154334> (2022).
- Platonova, S. et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. *Cancer Res.* **71**, 5412–5422 (2011).
- Sun, C. et al. High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. *Oncoimmunology* **6**, e1264562 (2017).
- Spanholtz, J. et al. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34<sup>+</sup> positive cells for adoptive cancer immunotherapy. *PLoS ONE* **5**, e9221 (2010).
- Dolstra, H. et al. Successful transfer of umbilical cord blood CD34<sup>+</sup> hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients. *Clin. Cancer Res.* **23**, 4107–4118 (2017).
- Liu, E. et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. *Leukemia* **32**, 520–531 (2018). **This article reports the first successful clinical application of CAR-modified NK immunotherapy in patients with CD19-positive haematologic malignancies.**
- Berrien-Elliott, M. M. et al. Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia. *Cancer Discov.* **10**, 1854–1871 (2020).
- Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. *N. Engl. J. Med.* **382**, 545–553 (2020).
- Gong, J.-H., Maki, G. & Klingemann, H. G. Characterization of a human cell line (NK-92) with phenotypic and functional characteristics of activated natural killer cells. *Leukemia* **8**, 652–658 (1994).
- Tang, X. et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. *Am. J. Cancer Res.* **8**, 1083–1089 (2018).
- Zhang, C. et al. Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. *Front. Immunol.* <https://doi.org/10.3389/fimmu.2017.00533> (2017).
- Hoogstad-van Evert, J. S. et al. Umbilical cord blood CD34<sup>+</sup> progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2R<sup>gnull</sup> mice. *Oncoimmunology* **6**, e1320630 (2017).
- Knorr, D. A. et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. *Stem Cell Transl. Med.* **2**, 274–283 (2013).
- Li, Y., Hermanson, D. L., Moriarty, B. S. & Kaufman, D. S. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. *Cell Stem Cell* **23**, 181–192.e5 (2018). **This article demonstrates the first successful generation of iPSC-derived CAR NK cells.**
- Goldenson, B. H. et al. Umbilical cord blood and iPSC-derived natural killer cells demonstrate key differences in cytotoxic activity and KIR profiles. *Front. Immunol.* **11**, <https://doi.org/10.3389/fimmu.2020.561553> (2020).
- Zhu, H. et al. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity. *Blood* **135**, 399–410 (2020).
- Kim, K. et al. Epigenetic memory in induced pluripotent stem cells. *Nature* **467**, 285–290 (2010).
- Bar-Nur, O., Russ, H. A., Efrat, S. & Benvenisty, N. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet  $\beta$  cells. *Cell Stem Cell* **9**, 17–23 (2011).
- Goodridge, J. P. et al. FT596: translation of first-of-kind multi-antigen targeted off-the-shelf CAR-NK cell with engineered persistence for the treatment of B cell malignancies. *Blood* **134**, 301–301 (2019).
- Bachanova, V. et al. Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed/refractory B-cell lymphoma. *Blood* **138**, 823 (2021).
- Goodridge, J. P. et al. Abstract 1550: FT576 path to first-of-kind clinical trial: translation of a versatile multi-antigen specific off-the-shelf NK cell for treatment of multiple myeloma. *Cancer Res.* **81**, 1550 (2021).
- Strati, P. et al. Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hNC16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL). *J. Clin. Oncol.* **39**, 7541–7541 (2021).
- Imai, C., Iwamoto, S. & Campana, D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. *Blood* **106**, 376–383 (2005). **This article describes the first successful generation of CAR NK cells using a 41BB-co-stimulated CD19-directed synthetic CAR.**

53. Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. *Science* **295**, 2097–2100 (2002). **This seminal work demonstrates that alloreactive NK cells confer a potent graft-versus-leukemia effect and protect against GVHD in recipients of T cell-depleted HLA-haploidentical allogeneic transplantation (TCLD-haplo-alloHSCT).**
54. Ruggeri, L. et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. *Blood* **94**, 335–339 (1999).
55. Davies, S. M. et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. *Blood* **100**, 3825–3827 (2002).
56. Ruggeri, L. et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. *Blood* **110**, 433–440 (2007).
57. Ciurea, S. O. et al. Decrease post-transplant relapse using donor-derived expanded NK-cells. *Leukemia* **36**, 155–164 (2022).
58. Hsu, K. C. et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. *Blood* **105**, 4878–4884 (2005).
59. Verheyden, S., Schots, R., Duquet, W. & Demanet, C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. *Leukemia* **19**, 1446–1451 (2005).
60. Venstrom, J. M. et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. *N. Engl. J. Med.* **367**, 805–816 (2012).
61. Boudreau, J. E. et al. KIR3DL1/HLA-B subtypes govern acute myelogenous leukemia relapse after hematopoietic cell transplantation. *J. Clin. Oncol.* **35**, 2268 (2017).
62. Schetelig, J. et al. External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails. *Blood* **135**, 1386–1395 (2020).
63. Beelen, D. W. et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. *Blood* **105**, 2594–2600 (2005).
64. Bishara, A. et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. *Tissue Antigens* **63**, 204–211 (2004).
65. Schaffer, M., Malmberg, K. J., Ringden, O., Ljunggren, H. G. & Remberger, M. Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. *Transplantation* **78**, 1081–1085 (2004).
66. Mehta, R. S. & Rezvani, K. Can we make a better match or mismatch with KIR genotyping? *Hematol. Am. Soc. Hematol. Educ. Program.* **2016**, 106–118 (2016).
67. Schmidts, A. et al. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. *Blood Adv.* **3**, 3248–3260 (2019).
68. Leivas, A. et al. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. *Blood Cancer J.* **11**, 146 (2021).
69. Chang, Y. H. et al. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. *Cancer Res.* **73**, 1777–1786 (2013).
70. Biederstädt, A. & Rezvani, K. Engineering the next generation of CAR-NK immunotherapies. *Int. J. Hematol.* **114**, 554–571 (2021).
71. Daher, M. & Rezvani, K. Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer. *Cancer Discov.* **11**, 45–58 (2021).
72. Lanier, L. L., Corliss, B. C., Wu, J., Leong, C. & Phillips, J. H. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. *Nature* **391**, 703–707 (1998). **This seminal article elucidates the role of DAP12 as an activating NK cell immunoreceptor through cross-linking with killer cell immunoglobulin-like receptor (KIR) family molecules.**
73. Zhao, R. et al. DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells. *Oncoimmunology* **8**, e1509175 (2018).
74. Ng, Y. Y. et al. T cells expressing NKG2D CAR with a DAP12 signaling domain stimulate lower cytokine production while effective in tumor eradication. *Mol. Ther.* **29**, 75–85 (2021).
75. Töpfer, K. et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. *J. Immunol.* **194**, 3201 (2015).
76. Billadeau, D. D., Upshaw, J. L., Schoon, R. A., Dick, C. J. & Leibson, P. J. NKG2D-DAP10 triggers human NK cell-mediated killing via a SYK-independent regulatory pathway. *Nat. Immunol.* **4**, 557–564 (2003). **This article uncovers the role of the activating NKG2D–DAP10 immune receptor recognition complex which can induce NK cell-mediated killing in a SYK-independent manner.**
77. Frigault, M. J. et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. *Cancer Immunol. Res.* **3**, 356–367 (2015).
78. Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. *Nat. Med.* **21**, 581–590 (2015). **This important article lays out the principle of antigen-independent tonic CAR signalling which can induce T cell exhaustion impairing antitumour efficacy.**
79. Watanabe, N. et al. Fine-tuning the CAR spacer improves T-cell potency. *Oncoimmunology* **5**, e1253656 (2016).
80. Mamonkin, M. et al. Tonic 4-1BB signaling from chimeric antigen receptors (CARs) impairs expansion of T cells due to Fas-mediated apoptosis. *J. Immunol.* **196** (Suppl 1), 143.7 (2016).
81. Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. *Nat. Med.* **25**, 82–88 (2019).
82. Bridgeman, J. S. et al. CD3 $\zeta$ -based chimeric antigen receptors mediate T cell activation via *cis*- and *trans*-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy. *Clin. Exp. Immunol.* **175**, 258–267 (2014).
83. Bridgeman, J. S. et al. The optimal antigen response of chimeric antigen receptors harboring the CD3 $\zeta$  transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. *J. Immunol.* **184**, 6938–6949 (2010).
84. Muller, Y. D. et al. The CD28-transmembrane domain mediates chimeric antigen receptor heterodimerization with CD28. *Front. Immunol.* **12**, 639818 (2021).
85. Savoldo, B. et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. *J. Clin. Invest.* **121**, 1822–1826 (2011).
86. Cronk, R. J., Zurko, J. & Shah, N. N. Bispecific chimeric antigen receptor T cell therapy for B cell malignancies and multiple myeloma. *Cancers* **12**, 2523 (2020).
87. Zah, E. et al. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. *Nat. Commun.* **11**, 2283 (2020).
88. Shah, N. N. et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. *Nat. Med.* **26**, 1569–1575 (2020).
89. Wallstabe, L. et al. ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. *JCI Insight* <https://doi.org/10.1172/jci.insight.126345> (2019).
90. Srivastava, S. et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. *Cancer Cell* **35**, 489–503.e8 (2019).
91. Cho, J. H. et al. Engineering advanced logic and distributed computing in human CAR immune cells. *Nat. Commun.* **12**, 792 (2021).
92. Garrison, B. S. et al. FLT3 OR CD33 NOT EMCN logic gated CAR-NK cell therapy (SENTI-202) for precise targeting of AML. *Blood* **138** (suppl. 1), 2799 (2021).
93. Gonzalez, A. et al. Abstract LB028: Development of logic-gated CAR-NK cells to reduce target-mediated healthy tissue toxicities. *Cancer Res.* **81**, LB028 (2021).
94. Mensali, N. et al. NK cells specifically TCR-dressed to kill cancer cells. *EBioMedicine* **40**, 106–117 (2019).
95. Shao, H. et al. TCR mispairing in genetically modified T cells was detected by fluorescence resonance energy transfer. *Mol. Biol. Rep.* **37**, 3951–3956 (2010).
96. Wiernik, A. et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 $\times$ 33 bispecific killer cell engager and ADAM17 inhibition. *Clin. Cancer Res.* **19**, 3844–3855 (2013).
97. Vallera, D. A. et al. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. *Cancer Biother. Radiopharm.* **28**, 274–282 (2013).
98. Gleason, M. K. et al. CD16 $\times$ CD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33 $^+$  targets. *Blood* **123**, 3016–3026 (2014).
99. Schmöhl, J., Gleason, M., Dougherty, P., Miller, J. S. & Vallera, D. A. Heterodimeric bispecific single chain variable fragments (scFv) killer engagers (BiKEs) enhance NK-cell activity against CD133 $^+$  colorectal cancer cells. *Target. Oncol.* **11**, 353–361 (2016).
100. Kerbauy, L. N. et al. Combining AFM13, a bispecific CD30/CD16A antibody, with cytokine-activated blood and cord blood-derived NK cells facilitates CAR-like responses against CD30 $^+$  malignancies. *Clin. Cancer Res.* **27**, 3744–3756 (2021).
101. Reusch, U. et al. A novel tetraivalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30 $^+$  tumor cells. *MAbs* **6**, 727–738 (2014).
102. Schmöhl, J. U. et al. Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker. *Oncotarget* **7**, 73830–73844 (2016).
103. Vallera, D. A. et al. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33 $^+$  targets while also inducing persistence, in vivo expansion, and enhanced function. *Clin. Cancer Res.* **22**, 3440–3450 (2016).
104. Schmöhl, J. U. et al. Engineering of anti-CD133 trispecific molecule capable of inducing NK expansion and driving antibody-dependent cell-mediated cytotoxicity. *Cancer Res. Treat.* **49**, 1140 (2017).
105. Arvindam, U. S. et al. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. *Leukemia* **35**, 1586–1596 (2021).
106. Gauthier, L. et al. Multifunctional natural killer cell engagers targeting Nkp46 trigger protective tumor immunity. *Clin. Cell* **177**, 1701–1713.e16 (2019). **This report outlines a novel tri-specific NK cell engager molecule that cross-links the two NK cell activating receptors CD16 and Nkp46 with a specific tumour antigen.**
107. US National Library of Medicine. *ClinicalTrials.gov* <https://clinicaltrials.gov/show/NCT04074746> (2020).
108. Bryceson, Y. T., March, M. E., Ljunggren, H. G. & Long, E. O. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. *Blood* **107**, 159–166 (2006).
109. Rosario, M. et al. The IL-15-based ALT-803 complex enhances Fc $\gamma$ R11a-triggered NK cell responses and in vivo clearance of B cell lymphomas. *Clin. Cancer Res.* **22**, 596–608 (2016).
110. de Rham, C. et al. The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. *Arthritis Res. Ther.* **9**, R125 (2007).
111. Gang, M. et al. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. *Blood* **136**, 2308–2318 (2020).
112. Dong, H. et al. Engineered memory-like NK cars targeting a neopeptide derived from intracellular NPM1c exhibit potent activity and specificity against acute myeloid leukemia. *Blood* **136**, 3–4 (2020).
113. Lasek, W., Zagożdżon, R. & Jakobiński, M. Interleukin 12: still a promising candidate for tumor immunotherapy? *Cancer Immunol. Immunother.* **63**, 419–435 (2014).
114. McMichael, E. L. et al. IL-21 enhances natural killer cell response to cetuximab-coated pancreatic tumor cells. *Clin. Cancer Res.* **23**, 489–502 (2017).
115. Miller, J. S. Therapeutic applications: natural killer cells in the clinic. *Hematology* **2013**, 247–253 (2013).
116. Anton, O. M. et al. *Trans*-endocytosis of intact IL-15Ra–IL-15 complex from presenting cells into NK cells favors signaling for proliferation. *Proc. Natl Acad. Sci. USA* **117**, 522–531 (2020).
117. Tarannum, M. & Romee, R. Cytokine-induced memory-like natural killer cells for cancer immunotherapy. *Stem Cell Res. Ther.* **12**, 592 (2021).
118. Felices, M. et al. Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. *JCI Insight* <https://doi.org/10.1172/jci.insight.96219> (2018).
119. Sarhan, D. et al. Adaptive NK cells resist regulatory T-cell suppression driven by IL37. *Cancer Immunol. Res.* **6**, 766–775 (2018).



120. Nuñez, S. Y. et al. Human M2 macrophages limit NK cell effector functions through secretion of TGF- $\beta$  and engagement of CD85j. *J. Immunol.* **200**, 1008–1015 (2018).
121. Tumino, N. et al. Interaction between MDSC and NK cells in solid and hematological malignancies: impact on HSCT. *Front. Immunol.* <https://doi.org/10.3389/fimmu.2021.638841> (2021).
122. Zalfa, C. & Paust, S. Natural killer cell interactions with myeloid derived suppressor cells in the tumor microenvironment and implications for cancer immunotherapy. *Front. Immunol.* <https://doi.org/10.3389/fimmu.2021.633205> (2021).
123. Ni, J. et al. Single-cell RNA sequencing of tumor-infiltrating NK cells reveals that inhibition of transcription factor HIF-1 $\alpha$  unleashes NK cell activity. *Immunity* **52**, 1075–1087.e8 (2020).
124. Van Wilpe, S. et al. Lactate dehydrogenase: a marker of diminished antitumor immunity. *Oncoimmunology* **9**, 1731942 (2020).
125. Cascone, T. et al. Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy. *Cell Metab.* **27**, 977–987.e4 (2018).
126. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT01791595> (2013).
127. Jin, D. et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. *Cancer Res.* **70**, 2245–2255 (2010).
128. Stagg, J. et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. *Proc. Natl. Acad. Sci. USA* **107**, 1547–1552 (2010).
129. Allard, B., Longhi, M. S., Robson, S. C. & Stagg, J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. *Immunol. Rev.* **276**, 121–144 (2017).
130. Perrot, I. et al. Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. *Cell Rep.* **27**, 2411–2425.e9 (2019).
131. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT04148937> (2020).
132. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT03454451> (2018).
133. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT03616886> (2018).
134. Young, A. et al. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. *Cancer Cell* **30**, 391–403 (2016).
135. Young, A. et al. A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. *Cancer Res.* **78**, 1003 (2018).
136. Lupo, K. & Matosevic, S. 123 Natural killer cells engineered with an inducible, responsive genetic construct targeting TIGIT and CD73 to relieve immunosuppression within the GBM microenvironment. *J. Immunother. Cancer* **8**, A74–A75 (2020).
137. Giuffrida, L. et al. CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. *Nat. Commun.* **12**, 3236 (2021).
138. Kim, T.-D. et al. Human microRNA-27a\* targets Prf1 and GzmB expression to regulate NK-cell cytotoxicity. *Blood, J. Am. Soc. Hematol.* **118**, 5476–5486 (2011).
139. Yvon, E. S. et al. Cord blood natural killer cells expressing a dominant negative TGF- $\beta$  receptor: implications for adoptive immunotherapy for glioblastoma. *Cytotherapy* **19**, 408–418 (2017).
140. Daher, M. et al. The TGF- $\beta$ /SMAD signaling pathway as a mediator of NK cell dysfunction and immune evasion in myelodysplastic syndrome. *Blood* **130**, 53–53 (2017).
141. Shaim, H. et al. Targeting the  $\alpha$ v integrin/TGF- $\beta$  axis improves natural killer cell function against glioblastoma stem cells. *J. Clin. Investig.* <https://doi.org/10.1172/JCI142116> (2021).
142. Stojanovic, A., Fiegler, N., Brunner-Weinzierl, M. & Cerwenka, A. CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN- $\gamma$  production in response to mature dendritic cells. *J. Immunol.* **192**, 4184–4191 (2014).
143. Russick, J. et al. Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. *J. Immunother. Cancer* **8**, e001054 (2020).
144. Sanseviero, E. et al. Anti-CTLA-4 activates intratumoral NK cells and combined with IL15/IL15Ra complexes enhances tumor control. *Cancer Immunol. Res.* **7**, 1371–1380 (2019).
145. Judge, S. J. et al. Minimal PD-1 expression in mouse and human NK cells under diverse conditions. *J. Clin. Investig.* **130**, 3051–3068 (2020).
146. Judge, S. J., Murphy, W. J. & Canter, R. J. Characterizing the dysfunctional NK cell: assessing the clinical relevance of exhaustion, anergy, and senescence. *Front. Cell Infect. Microbiol.* **10**, 49–49 (2020).
147. Davis, Z. et al. Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. *Blood Adv.* **5**, 1069–1080 (2021).
148. Hsu, J. et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. *J. Clin. Investig.* **128**, 4654–4668 (2018).
149. Dong, W. et al. The mechanism of anti-PD-L1 antibody efficacy against PD-L1-negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector. *Cancer Discov.* **9**, 1422–1437 (2019).
150. Newman, J. & Horowitz, A. NK cells seize PD1 from leukemia cells. *Nat. Rev. Immunol.* **21**, 345–345 (2021).
151. Wilk, A. J. et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. *Nat. Med.* **26**, 1070–1076 (2020).
152. da Silva, I. P. et al. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. *Cancer Immunol. Res.* **2**, 410–422 (2014).
153. Farkas, A. M. et al. Tim-3 and TIGIT mark natural killer cells susceptible to effector dysfunction in human bladder cancer. *J. Immunol.* **200**, 124.114 (2018).
154. Chauvin, J.-M. et al. IL15 stimulation with TIGIT blockade reverses CD155-mediated NK-cell dysfunction in melanoma. *Clin. Cancer Res.* **26**, 5520–5533 (2020).
155. Sarhan, D. et al. Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cells. *Cancer Res.* **76**, 5696–5706 (2016).
156. Zhang, Q. et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. *Nat. Immunol.* **19**, 723–732 (2018).
157. Ali, A. et al. LAG-3 modulation of natural killer cell immunoregulatory function. *J. Immunol.* **202**, 76.77 (2019).
158. Kohrt, H. E. et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. *Blood* **123**, 678–686 (2014).
159. Vey, N. et al. Randomized phase 2 trial of Lirilumab (anti-KIR monoclonal antibody, mAb) as maintenance treatment in elderly patients (pts) with acute myeloid leukemia (AML): results of the Effikir trial. *Blood* **130**, 889–889 (2017).
160. Vey, N. et al. A phase 1 study of Lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. *Oncotarget* **9**, 17675–17688 (2018).
161. Kim, S. et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. *Nature* **436**, 709–713 (2005).
- This seminal work lays out the concept of NK cell ‘licensing’ through which NK cells acquire functional competence and self-tolerance by interaction of inhibitory receptors and self-MHC molecules.**
162. Kim, S. et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. *Proc. Natl. Acad. Sci. USA* **105**, 3053–3058 (2008).
163. André, P. et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. *Cell* **175**, 1731–1743.e13 (2018).
164. Kamiya, T., Seow, S. V., Wong, D., Robinson, M. & Campana, D. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. *J. Clin. Investig.* **129**, 2094–2106 (2019).
165. Delconte, R. B. et al. CIS is a potent checkpoint in NK cell-mediated tumor immunity. *Nat. Immunol.* **17**, 816–824 (2016).
- This important article identifies the intracellular NK cell checkpoint CIS, which negatively regulates IL-15 signalling.**
166. Delconte, R. B. et al. NK cell priming from endogenous homeostatic signals is modulated by CIS. *Front. Immunol.* <https://doi.org/10.3389/fimmu.2020.00075> (2020).
167. Daher, M. et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. *Blood* **137**, 624–636 (2021).
168. Zhu, H. et al. Metabolic reprogramming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity. *Cell Stem Cell* **27**, 224–237.e6 (2020).
169. Coca, S. et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. *Cancer* **79**, 2320–2328 (1997).
170. Ishigami, S. et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. *Cancer* **88**, 577–583 (2000).
171. Villegas, F. R. et al. Prognostic significance of tumor-infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. *Lung Cancer* **35**, 23–28 (2002).
172. Donskov, F. & von der Maase, H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. *J. Clin. Oncol.* **24**, 1997–2005 (2006).
173. Geissler, K. et al. Immune signature of tumor-infiltrating immune cells in renal cancer. *Oncoimmunology* **4**, e985082 (2015).
174. Wendel, M., Galani, I. E., Suri-Payer, E. & Cerwenka, A. Natural killer cell accumulation in tumors is dependent on IFN- $\gamma$  and CXCR3 ligands. *Cancer Res.* **68**, 8437–8445 (2008).
175. Mlecniak, B. et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. *Gastroenterology* **138**, 1429–1440 (2010).
176. Park, M. H., Lee, J. S. & Yoon, J. H. High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8<sup>+</sup> T cells, natural killer cells, and dendritic cells in breast carcinoma. *J. Surg. Oncol.* **106**, 386–392 (2012).
177. Castriconi, R. et al. Molecular mechanisms directing migration and retention of natural killer cells in human tissues. *Front. Immunol.* **9**, 2324 (2018).
178. Levy, E. R., Clara, J. A., Reger, R. N., Allan, D. S. J. & Childs, R. W. RNA-seq analysis reveals CCR5 as a key target for CRISPR gene editing to regulate in vivo NK cell trafficking. *Cancers* <https://doi.org/10.3390/cancers13040872> (2021).
179. Wennerberg, E., Kremer, V., Childs, R. & Lundqvist, A. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. *Cancer Immunol. Immunother.* **64**, 225–235 (2015).
180. Somanchi, S. S., Somanchi, A., Cooper, L. J. N. & Lee, D. A. Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. *Blood* **119**, 5164–5172 (2012).
181. Carlsten, M. et al. Efficient mRNA-based genetic engineering of human NK cells with high-affinity CD16 and CCR7 augments rituximab-induced ADCC against lymphoma and targets NK cell migration toward the lymph node-associated chemokine CCL19. *Front. Immunol.* **7**, 105 (2016).
182. Müller, N. et al. Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1 $\alpha$ -secreting glioblastoma. *J. Immunother.* **38**, 197 (2015).
183. Kremer, V. et al. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma. *J. Immunother. Cancer* **5**, 73 (2017).
184. Ponzetta, A. et al. Multiple myeloma impairs bone marrow localization of effector natural killer cells by altering the chemokine microenvironment. *Cancer Res.* **75**, 4766–4777 (2015).
185. Bonanni, V., Antonangeli, F., Santoni, A. & Bernardini, G. Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells. *J. Immunother. Cancer* **7**, 290 (2019).
186. Lee, J. et al. An antibody designed to improve adoptive NK-cell therapy inhibits pancreatic cancer progression in a murine model. *Cancer Immunol. Res.* **7**, 219 (2019).
187. Ng, Y. Y., Tay, J. C. & Wang, S. CXCR1 expression to improve anti-cancer efficacy of intravenously injected CAR-NK cells in mice with peritoneal xenografts. *Mol. Ther. Oncolytics* **16**, 75–85 (2020).
188. Walle, T. et al. Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8. *Sci. Adv.* **8**, eabh4050 (2022).
189. Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. *Nat. Rev. Cancer* **21**, 145–161 (2021).
190. Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. *Blood Cancer J.* **11**, 69 (2021).
191. Gill, S. & Brudno, J. N. CAR T-cell therapy in hematologic malignancies: clinical role, toxicity, and unanswered questions. *Am. Soc. Clin. Oncol. Educ. Book* [https://doi.org/10.1200/EDBK\\_320085](https://doi.org/10.1200/EDBK_320085) (2021).
192. Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. *Nat. Rev. Clin. Oncol.* **16**, 372–385 (2019).

193. Strati, P. & Neelapu, S. S. CAR-T failure: beyond antigen loss and T cells. *Blood* **137**, 2567–2568 (2021).

194. Biederstädt, A. & Rezvani, K. How I treat high-risk acute myeloid leukemia using pre-emptive adoptive cellular immunotherapy. *Blood* <https://doi.org/10.1182/blood.202101.2411> (2022).

195. Abdel-Hakeem, M. S. et al. Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation. *Nat. Immunol.* **22**, 1008–1019 (2021). **This article elucidates how exhausted T cell subsets fail to restore their full functional capacity upon elimination of antigenic stimulation due to persistent epigenetic scarring.**

196. Yates, K. B. et al. Epigenetic scars of CD8<sup>+</sup> T cell exhaustion persist after cure of chronic infection in humans. *Nat. Immunol.* **22**, 1020–1029 (2021). **This report demonstrates the fixed nature of exhausted T cell epigenetic signatures following resolution of chronic antigenic stimulation.**

197. Biederstädt, A. et al. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. *Gut* **69**, 1472–1482 (2020).

198. Kumar, S. et al. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model. *Gut* <https://doi.org/10.1136/gutjnl-2021-324834> (2022).

199. Demel, U. M. et al. Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer. *J. Clin. Investig.* <https://doi.org/10.1172/JCI152383> (2022).

200. Saha, K. et al. The NIH Somatic Cell Genome Editing program. *Nature* **592**, 195–204 (2021). **This report lays out the aims and scope of the NIH SCGE Consortium.**

201. Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR–Cas nucleases. *Nat. Biotechnol.* **33**, 187–197 (2015).

202. Tsai, S. Q. et al. CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR–Cas9 nuclease off-targets. *Nat. Methods* **14**, 607–614 (2017).

203. Dobosy, J. R. et al. RNase H-dependent PCR (rhPCR): improved specificity and single nucleotide polymorphism detection using blocked cleavable primers. *BMC Biotechnol.* **11**, 80 (2011).

204. Hu, J. et al. Detecting DNA double-stranded breaks in mammalian genomes by linear amplification-mediated high-throughput genome-wide translocation sequencing. *Nat. Protoc.* **11**, 853–871 (2016).

205. Gillmore, J. D. et al. CRISPR–Cas9 in vivo gene editing for transthyretin amyloidosis. *N. Engl. J. Med.* **385**, 493–502 (2021). **This seminal work demonstrates the first successful clinical application of in vivo CRISPR–Cas9 gene editing.**

206. Aghajanian, H. et al. Targeting cardiac fibrosis with engineered T cells. *Nature* **573**, 430–433 (2019).

207. Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. *Science* **375**, 91–96 (2022). **This study demonstrates the first successful in vivo engineering of CAR T cells using a CD5-directed lipid nanoparticle containing CAR-encoding mRNA.**

208. Bender, R. R., Muth, A., Schneider, I. C., Maisner, A. & Buchholz, C. J. Developing an engineered nipah virus glycoprotein based lentiviral vector system retargeted to cell surface receptors of choice. *Mol. Ther.* **23**, S2 (2015).

209. Micklenthwaite, K. P. et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. *Blood* **138**, 1391–1405 (2021).

210. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT02742727> (2016).

211. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT00995137> (2009).

212. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT01974479> (2013).

213. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT02892695> (2016).

214. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT03056339> (2017).

215. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT03824951> (2019).

216. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT03690310> (2019).

217. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT05020678> (2021).

218. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT04245722> (2020).

219. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT04639739> (2020).

220. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT04887012> (2021).

221. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT04796675> (2021).

222. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT04796688> (2021).

223. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT05379647> (2021).

224. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT05336409> (2022).

225. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT04023071> (2019).

226. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT03692767> (2019).

227. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT03824964> (2019).

228. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT02944162> (2016).

229. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT05008575> (2021).

230. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT05215015> (2020).

231. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT05092451> (2022).

232. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT03559764> (2018).

233. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT03940833> (2019).

234. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT05008536> (2021).

235. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT05182073> (2021).

236. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT04614636> (2020).

237. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT04623944> (2020).

238. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT03415100> (2018).

239. Xiao, L. et al. Adoptive transfer of NKGD2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. *Mol. Ther.* **27**, 1114–1125 (2019).

240. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT05213195> (2021).

241. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT05247957> (2021).

242. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT02839954> (2016).

243. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT03383978> (2017).

244. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT03692663> (2018).

245. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT03692637> (2019).

246. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT04630769> (2021).

247. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT03940820> (2019).

248. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT03931720> (2019).

249. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT03941457> (2019).

250. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT04551885> (2020).

251. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT04847466> (2021).

252. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT05194709> (2021).

253. US National Library of Medicine. *ClinicalTrials.gov* <https://ClinicalTrials.gov/show/NCT04324996> (2020).

254. Wu, L. et al. Irenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20<sup>+</sup> tumor cells. *Clin. Cancer Res.* **14**, 4650–4657 (2008).

255. Tai, Y. T. et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. *Cancer Res.* **65**, 11712–11720 (2005).

256. Nahas, M. R. et al. Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine. *Br. J. Haematol.* **185**, 679–690 (2019).

257. Hicks, K. C. et al. Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. *Oncimmunology* **7**, e1466018 (2018).

258. Leung, E. Y. L. et al. NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer. *Mol. Ther. Oncolytics* **16**, 289–301 (2020).

259. Marotel, M., Hasim, M. S., Hagerman, A. & Ardolino, M. The two faces of NK cells in oncolytic virotherapy. *Cytokine Growth Factor Rev.* **56**, 59–68 (2020).

260. Cichocki, F. et al. GSK3 inhibition drives maturation of NK cells and enhances their antitumor activity. *Cancer Res.* **77**, 5664–5675 (2017).

261. Parameswaran, R. et al. Repression of GSK3 restores NK cell cytotoxicity in AML patients. *Nat. Commun.* **7**, 11154 (2016).

262. van Hall, T. et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. *J. Immunother. Cancer* **7**, 263 (2019).

263. Yalniz, F. F. et al. A pilot trial of Lirilumab with or without azacitidine for patients with myelodysplastic syndrome. *Clin. Lymphoma Myeloma Leuk.* **18**, 658–663.e2 (2018).

264. Bachier, C. et al. A phase 1 study of NKX101, an allogeneic CAR natural killer (NK) cell therapy, in subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS). *Blood* **136**, 42–43 (2020).

265. Pinz, K. G. et al. Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells. *Oncotarget* **8**, 112783–112796 (2017).

266. Romanski, A. et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. *J. Cell Mol. Med.* **20**, 1287–1294 (2016).

267. You, F. et al. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. *Am. J. Cancer Res.* **9**, 64–78 (2019).

268. Xu, Y. et al. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies. *J. Hematol. Oncol.* **12**, 49 (2019).

269. Martin, E. M. et al. Exploring NKG2D and BCMA-CAR NK-92 for adoptive cellular therapy to multiple myeloma. *Clin. Lymphoma, Myeloma Leuk.* **19**, e24–e25 (2019).

270. Jiang, H. et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. *Mol. Oncol.* **8**, 297–310 (2014).

271. Han, J. et al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. *Sci. Rep.* **5**, 11483 (2015).

272. Chu, J. et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. *Leukemia* **28**, 917–927 (2014).

273. Chen, K. H. et al. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. *Leukemia* **31**, 2151–2160 (2017).

274. Chen, K. H. et al. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. *Oncotarget* **7**, 56219–56232 (2016).

275. Vallera, D. A. et al. NK-cell-mediated targeting of various solid tumors using a B7-H3 tri-specific killer engager in vitro and in vivo. *Cancers* <https://doi.org/10.3390/cancers12092659> (2020).

276. Cooper, L. J. et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. *Blood* **101**, 1637–1644 (2003).

277. Imai, C. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. *Leukemia* **18**, 676–684 (2004).

278. Maher, J., Brentjens, R. J., Gunset, G., Riviere, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR/CD28 receptor. *Nat. Biotechnol.* **20**, 70–75 (2002).

279. Schubert, M.-L. et al. Third-generation CAR T cells targeting CD19 are associated with an excellent safety profile and might improve persistence of CAR T cells in treated patients. *Blood* **134**, 51–51 (2019).

280. Bjordahl, R. et al. Abstract 1539: development of off-the-shelf B7H3 chimeric antigen receptor NK cell therapeutic with broad applicability across many solid tumors. *Cancer Res.* **81**, 1539 (2021).

281. Basar, R. et al. Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. *Cell Rep.* <https://doi.org/10.1016/j.celrep.2021.109432> (2021).

282. Shalem, O. et al. Genome-scale CRISPR–Cas9 knockout screening in human cells. *Science* **343**, 84–87 (2014).

283. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR–Cas9 system. *Science* **343**, 80–84 (2014).

284. Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. *Nature* **547**, 413–418 (2017).
285. Patel, S. J. et al. Identification of essential genes for cancer immunotherapy. *Nature* **548**, 537–542 (2017).
286. Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. *Science* **359**, 770–775 (2018).
287. Shang, W. et al. Genome-wide CRISPR screen identifies FAM49B as a key regulator of actin dynamics and T cell activation. *Proc. Natl Acad. Sci.* **115**, E4051 (2018).
288. Ishizuka, J. J. et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. *Nature* **565**, 43–48 (2019).
289. Lawson, K. A. et al. Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. *Nature* **586**, 120–126 (2020).
290. Sheffer, M. et al. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. *Nat. Genet.* **53**, 1196–1206 (2021).  
**This report uses an orthogonal approach combining genome-wide CRISPR screening with multiplexed cancer cell line screening to decipher cancer type-specific vulnerabilities towards NK cells.**
291. Ting, P. Y. et al. Guide Swap enables genome-scale pooled CRISPR–Cas9 screening in human primary cells. *Nat. Methods* **15**, 941–946 (2018).
292. Shifrut, E. et al. Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function. *Cell* **175**, 1958–1971.e15 (2018).
293. Wang, D. et al. CRISPR screening of CAR T cells and cancer stem cells reveals critical dependencies for cell-based therapies. *Cancer Discov.* **11**, 1192–1211 (2021).
294. Roth, T. L. et al. Pooled knockin targeting for genome engineering of cellular immunotherapies. *Cell* **181**, 728–744.e21 (2020).
295. Legut, M. et al. A genome-scale screen for synthetic drivers of T cell proliferation. *Nature* **603**, 728–735 (2022).

#### Acknowledgements

The authors thank J. S. Moyes for providing editing support during the preparation of this manuscript. A.B. received support from the German Research Foundation as Walter Benjamin Postdoctoral Fellow (464778766). This work was supported, in part, by generous philanthropic contributions to The University of Texas MD Anderson Cancer Center Moon Shots Program, The Sally Cooper Murray endowment, generous support of Ann and Clarence Cazalot, and Lyda Hill Philanthropies; and by grants from CPRIT (RP160693), a Stand Up To Cancer Dream Team Research Grant (Grant number: SU2C-AACR-DT-29-19), grants from the National Institutes of Health (NIH) (1 R01 CA211044-01, 5 P01CA148600-03, and P50CA100632-16), the Specialized

Program of Research Excellence (SPORE) in Brain Cancer Grant (P50CA127001) and a grant to MD Anderson Cancer Center from the NIH (CA016672). The SU2C research grant is administered by the American Association for Cancer Research, the scientific partner of SU2C.

#### Author contributions

The authors contributed equally to all aspects of the article.

#### Competing interests

K.R. and The University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Takeda Pharmaceutical and Affimed GmbH. K.R. participates on the Scientific Advisory Board for GemoAb, AvengeBio, Virogin Biotech, GSK, Bayer, Navan Technologies and Caribou Biosciences. The remaining authors declare no competing interests.

#### Peer review information

*Nature Reviews Cancer* thanks E. Vivier, who co-reviewed with P. Andre, and A. Cerwenka and S. Gill for their contribution to the peer review of this work.

#### Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© Springer Nature Limited 2022